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introduction
What’s in a name? Since the first description of age-related macular degeneration 
in 1874 as “Symmetrical central choroido-retinal disease occurring in senile per-
sons”,1 over 20 different names have been given to this disorder, often reflecting the 
pathophysiological thinking at a certain time. Because there was need for an inter-
nationally accepted classification, the International ARM Epidemiological Study 
Group named all signs of age-related macular changes age-related maculopathy 
(ARM), and its end stages, age-related macular degeneration (AMD) following the 
convention at that time.2 Both the laymen and the medical public found these two 
names confusing, so gradually all ARM was called AMD, to be divided in early and 
late AMD. Recently it was proposed to use AMD as an acronym for “Aging Macula 
Disorder”, essentially the same disease as age-related macular degeneration, for 
the following reasons.3 Age-related does not differentiate between juvenile macu-
lar disease and that associated with old age. Aging better describes the process of 
becoming older. Although AMD is a complex disorder with a large genetic compo-
nent, the lifelong changes in the retinal pigment epithelium (RPE) and surrounding 
tissues in the macula seem a key component in its pathogenesis. Patients do not 
like to hear associations with senility anymore, nor with degeneration. Finally, it 
is not clear if and when early or late AMD becomes a disease, therefore we prefer 
calling it a disorder. Thus we opted for using aging macula disorder as the basis for 
AMD in this thesis.
Aging macula disorder (AMD) is a progressive disorder affecting the central part 
of the retina, the macula lutea. The macula is the specialized region of the retina 
responsible for the ability to see fine details. Deterioration of the macular area, and 
essentially its central point, the fovea, impairs contrast sensitivity and thus the abil-
ity of patients to conduct a wide range of activities, including recognizing familiar 
faces, reading, watching television, driving, and cycling. Most of these activities only 
can be performed with a visual acuity above 0.2 or 0.3. Because the visual acuity 
drops fast, the more eccentric to the fovea one fixates, we call this acuity range cen-
tral visual acuity, in contrast to the lower visual acuity in the periphery of and out-
side the macula. AMD patients have impaired central vision, and because peripheral 
vision usually remains intact, AMD does not cause total blindness when defined as 
loss of all light perception. This can make it difficult for family and friends of patients 
to understand why patients can navigate through a room effortlessly, even though 
they cannot read or drive. The impact of this visual handicap can be huge, especially 
in case of rapid visual acuity loss that may occur in the wet or neovascular type of 
late AMD. Patients and their partners need to deal with the emotional shock that 
rapid loss of vision will probably bring, and reorganize their way of living. 
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The diagnosis of AMD usually is made by funduscopy, looking at the inner poste-
rior part of the eye. Based on fundus signs AMD can be divided into early and late 
AMD. Early AMD is characterized by the appearance of white subretinal deposits, 
so-called drusen, and pigmentary abnormalities in the RPE. Most patients with early 
AMD are asymptomatic, although some psychophysical tests, for example recov-
ery time after a strong light stimulus, are abnormal.4 Late AMD can be subdivided 
in two distinct end stages, dry AMD and wet AMD, and is associated with severe 
central visual loss. Dry AMD is characterized by degeneration of the RPE, leading 
to a loss of photoreceptors. In cases of wet AMD new blood vessels form under the 
retina, leading to RPE detachment or sub retinal hemorrhage, resulting in fibrovas-
cular disciform scarring in the macular area. Severe vision loss in dry AMD usually 
progresses over the course of years, while patients with wet AMD may lose central 
vision overnight. Based on our data, we estimated that of the more than 4 million 
persons over 55 years living in the Netherlands,5 approximately 400.000 (9.2%) 
persons have early AMD and more than 70.000 (1.7%) have late AMD. It has been 
predicted that in our rapidly aging population, by 2020 the number of blind persons 
due to AMD will double unless better prevention and therapy will be found.6 The 
fast growing burden to public health makes it important to identify strategies for 
this disorder. Although AMD is now the leading cause of incurable blindness in the 
Western world,7-9 there is a low public awareness of AMD. It is essential to inform 
the population about primary prevention and symptoms of especially beginning 
wet AMD because for the latter new therapeutic strategies became available.10 AMD 
is considered to be a multifactorial disease, which means that both environmental 
and genetic factors play a role in its development. The pathogenesis of AMD is not 
yet elucidated, however several epidemiological studies have tried to shed light 
on various factors associated with AMD. As indicated by the name, age is a strong 
risk factor and the prevalence and incidence of AMD rise steeply with increasing 
age. The most consistent modifiable risk factor found for AMD is smoking.11 Other 
risk factors include atherosclerosis, a diet low in antioxidants, zinc and fatty fish, 
and potentially hypertension, high cholesterol levels, and sunlight exposure.12 Over 
the years, twin studies, research into familial aggregation and segregation analyses 
have provided compelling evidence for a strong role of genetics in AMD.13 Recently, 
a major risk variant was identified in the complement factor H gene. This Y402H 
single nucleotide polymorphism (SNP) in the complement factor H gene is thought 
to explain between 24 and 54% of all AMD cases.3 It has been reported that blacks 
have a lower prevalence of AMD than whites.14, 15 However, CFH genotype frequen-
cies are similar in blacks and whites, suggesting that other, yet unidentified, genetic 
or environmental risk factors are important in the pathogenesis of AMD. The search 
for genetic risk factors for AMD is rapidly progressing, and recent studies have 
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suggested that SNPs in the LOC387715, C2/FB and HTRA1 genes are also strongly 
associated with AMD.16-19
The aim of the epidemiological studies described in this thesis was to identify exter-
nal and genetic factors that are involved in the pathogenesis of AMD. All studies 
were performed within the context of the Rotterdam Study, a large-scale popula-
tion-based prospective cohort study among 7983 participants (response rate 78%) 
aged 55 years and older living in a suburb of Rotterdam. In epidemiologic studies 
we prefer not to speak of patients but of persons or participants. chapter 2 presents 
studies on environmental risk factors for AMD. Because recent evidence has shown 
a possible benefit of antioxidant and zinc intake in reducing loss of visual function 
due to AMD,20 we investigated whether dietary intake of antioxidant micronutrients 
was associated with a decreased risk of AMD (chapter 2.1). It has been suggested 
that inflammation plays a role in the pathogenesis of AMD,21 therefore we assessed 
the association between serum C-reactive protein levels and AMD (chapter 2.2). We 
also examined the association between alcohol consumption and the risk of AMD 
(chapter 2.3), a possible modifiable risk factor. chapter 3 contains studies on the 
association between genetic polymorphisms and AMD. Some studies proposed a 
protective effect of estrogen on AMD,22 subsequently we studied a genetic variation 
in the estrogen receptor 1 gene (chapter 3.1). Growth factors have been implicated 
in the pathogenesis of AMD and especially in wet AMD.23, 24 For this reason we exam-
ined genetic variations in the insulin-like growth factor gene 1 (chapter 3.2) and in 
the vascular endothelial growth factor gene (chapter 3.3). Finally in chapter 4, we 
reflect on our main findings, discuss relevant methodological aspects, and provide 
suggestions for further research.
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Dietary intake of antioxidants and 
risk of aging macula disorder
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ABstrAct
context: Aging macula disorder (AMD) is the most prevalent cause of irreversible 
blindness in the developed countries. Recently, high-dose supplementation with 
beta carotene, vitamins C and E, and zinc was shown to slow the progression of 
AMD. 
objective: To investigate whether regular dietary intake of antioxidants is associ-
ated with a lower risk of AMD.
design: Dietary intake was assessed at baseline in the Rotterdam Study (1990-1993) 
using a semiquantitative food frequency questionnaire. Incident AMD until final fol-
low-up in 2004 was determined by grading fundus color transparencies in a masked 
way according to the International Classificat ion and Grading System.
setting: Population-based cohort study of all inhabitants aged 55 years or older in 
a middle-class suburb of Rotterdam, the Netherlands.
Participants: Of 5836 persons at risk of AMD at baseline, 4765 had reliable dietary 
data, and 4170 participated in the follow-up.
main outcome measure: Incident AMD, defined as soft distinct drusen with pig-
ment alterations, indistinct or reticular drusen, geographic atrophy, or choroidal 
neovascularization. 
results: Incident AMD occurred in 560 participants after a mean follow-up of 8.0 
years (range, 0.3-13.9 years). Dietary intake of both vitamin E and zinc was inversely 
associated with incident AMD. The hazard ratio (HR) per standard devia t ion increase 
of intake for vitamin E was 0.92 (95% confidence interval (CI), 0.84 - 1.00) and for 
zinc was 0.91 (95% CI, 0.83- 0.98). An above-median intake of all 4 nutrients, beta 
carotene, vitamin C, vitamin E, and zinc, was associated with a 35% reduced risk (HR, 
0.65; 95% CI, 0.46 - 0.92) of AMD. Exclusion of supplement users did not affect the 
results. 
conclusions: In this study, a high dietary intake of beta carotene, vitamins C and 
E, and zinc was associated with a substantially reduced risk of AMD in elderly per-
sons.
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introduction
Aging macula disorder (AMD) is a degenerative disorder of the macula, the central 
part of the retina. Late AMD results in an inability to read, recognize faces, drive, or 
move freely. Early AMD is the subclinical stage of the disease and can be diagnosed 
by funduscopy. The prevalence of late AMD steeply increases with age, affecting 
11.5% of white persons older than 80 years.1 In the absence of effective treatment for 
AMD, the number of patients severely disabled by late AMD is expected to increase 
in the next 20 years by more than 50% to 3 million in the United States alone.1
The pathophysiology of AMD is still poorly understood, and AMD may in fact be a 
constellation of diseases with different causes. As in other age-related disorders, 
oxidative stress has been implicated in the etiology of AMD.2 The retina seems par-
ticularly susceptible to oxidative stress because of its high concentration of oxygen, 
polyunsaturated fatty acids, and photosensitizers, in combination with an intense 
exposure to light.3 Epi dem iol ogical studies evaluating both dietary intake and serum 
levels of antioxidant vitam ins and AMD have provided conflicting results.4-7 In the 
randomized, placebo-controlled Age-Related Eye Disease Study (AREDS), supple-
ments containing 5 to 13 times the recom mended daily allowance (RDA) of beta 
carotene, vitamins C and E, and zinc given to participants from retinal clinics with 
early or monocular late AMD resulted in a 25% reduction in the 5-year progression 
to late AMD.8 We sought to investigate whether antioxidants, as present in normal 
daily foods, may play a role in the primary prevention of AMD. 
methods
Study population
The Rotterdam Study is a population-based, prospective cohort study of the fre-
quency and determinants of common cardiovascular, locomotor, neurologic, and 
ophthalmologic diseases.9, 10 The eligible population comprised all 10,275 inhabit-
ants aged 55 years or older of a middle-class suburb of Rotterdam, the Netherlands, 
of whom 7,983 (78%) participated. Because the ophthalmologic part of the study 
became operational after the pilot phase of the study had started, 6,780 (66%) took 
part in the ophthalmic examinations. A baseline home interview and examinations 
at the study center were performed from 1990 to mid 1993, followed by a first fol-
low-up examination from 1993 to 1994, a second from mid 1997 to the end of 1999, 
and a third examination from 2000 to the end of 2004. Written informed consent 
was obtained from all participants. The medical ethics committee of Erasmus Uni-
versity approved the study protocol.
24
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Diagnosis of AMD 
The eye examination included 35° fundus photography (Topcon TRV-50VT fundus 
camera, Topcon Optical Co, Tokyo, Japan) after pharmacological mydriasis.10 Trans-
parencies were graded with 12.5x magnification according to the International 
Classification and Grading System.11 Two experienced graders, masked to dietary 
intake, graded the follow-up transparencies and afterward compared these with the 
baseline ones. The grading procedures, definitions, and graders were identical at 
baseline and follow-up. Consensus sessions and between-grader comparisons were 
performed regularly. Weighted kappa values were 0.72 for soft distinct drusen, 0.80 
for hyperpigment ation, and 0.58 for hypopigmentation.
Early AMD was defined as the presence of either large (≥ 63 µm), soft, distinct dru-
sen with pigment irregularities or indistinct (≥ 125 µm) or reticular drusen with 
or without pigment irregularities. Drusen are white deposits in the retina that are 
considered to be the hallmark of early AMD and are important predictors of late 
AMD.10, 12 Late AMD, mostly leading to blindness, was defined as dry (geographic 
atrophy) and wet (neovascular) AMD, or a combination of both.11 
Dietary assessment
At baseline, participants completed a checklist at home that queried foods and 
drinks they had consumed at least twice a month during the preceding year as 
well as dietary habits, use of supplements, and prescribed diets. Next, during their 
visit to the research center, they underwent a standardized interview by a dietitian 
based on the checklist, using a 170-item semi-quantitative food frequency ques-
tionnaire.13, 14 A validation study comparing this questionnaire with a 2-week food 
diary demonstrated reproducible and valid estimates.13, 14 These dietary data were 
converted to total energy intake and nutrient intake per day with the computerized 
Dutch Food Composition Table.15 For the current study, we selected the carotenoids 
alpha and beta carotene, beta crypto xanthin, lutein/zeaxanthin, lycopene, vita-
mins A (retinol equivalents), C and E, and iron and zinc as cofactors for antioxidant 
enzymes. Persons, who reported taking supplements containing carotenoids, vita-
mins A, C, or E, iron, or zinc, as well as multivitamins or multiminerals, were classified 
as supplement users.
Assessment of confounders
Information on potential confounders was collected at baseline. Smoking status 
was categorized as current, former or never, and number of pack-years was calcu-
lated. Serum total cholesterol level was measured in nonfasting blood samples with 
an automated enzymatic procedure. Blood pressure was defined as the mean of 2 
measure ments in sitting position at the right brachial artery with a random zero 
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sphygmomano meter. The ankle-arm index was calculated by taking the ratio of 
the systolic blood pressure at the ankle to the systolic blood pressure at the arm, 
using the lowest ratio of both legs. Carotid intima-media thickness and atheroscle-
rotic plaques were assessed ultrasonograph ic ally and aortic calcifications on lateral 
radiographic films of the lumbar spine. A sub clinical atherosclerosis composite 
score (range, 1-4) was constructed by summing points for the population-based 
deciles of carotid wall thickness and ankle-arm index, with points added for the 
presence of carotid plaques and aortic calcifications.16
Study sample
The cohort at risk consisted of 5836 persons with no AMD in either eye at baseline; 
i.e. with no drusen or pigment irregularities, hard drusen only, or soft drusen with-
out pigment irregularities. Incidence of AMD was defined as the presence of early or 
late AMD in at least 1 eye at 1 of the follow-up examinations. Persons with incident 
AMD (iAMD) were compared with those with no AMD at baseline and no AMD at any 
follow-up examinations.
Dietary intake was not assessed in 227 participants with decreased cognitive func-
tion (defined as a score < 80 on the Cambridge Examination of Mental Disorders in 
the Elderly),17 because their dietary history was deemed unreliable. We also exclud-
ed 179 nursing home residents because their food was prepared by nursing home 
staff and would not reflect past dietary habits. Reliable dietary data were missing in 
665 participants because of logical inconsistencies in dietary interviews, to missing 
the baseline dietitian visit when the food-frequency questionnaire was adminis-
tered, or to various other logistical reasons. Baseline characteristics were similar in 
the 2 groups, although eligible respond ents without dietary data were, on average, 
somewhat older compared with those with data and included fewer women.
Of this baseline cohort, 156 participants died, 419 refused any follow-up examina-
tion, and 20 were lost to follow up before the first follow-up examination. Non-
participants tended to be older; included more women, nursing home residents, 
and smokers; and more often had systemic hypertension. They did not differ from 
participants in their dietary intake of antioxidants; e.g., vitamin E (p = 0.75) or zinc 
(p = 0.69). The study sample thus consisted of 4170 participants who had normal 
cognition, lived independently, had reliable dietary assessment and gradable fun-
dus transparencies, and participated in at least 1 follow-up examination.
Data analysis
We adjusted the dietary intake of antioxidant nutrients for the total energy intake by 
means of the residual method described by Willett.18 For each nutrient, linear regres-
sion analysis was performed with antioxidant intake as the dependent variable and 
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total energy intake as the independent variable. This regression equation was used 
to calculate the expected mean antioxidant intake of the study population for the 
mean total energy intake of the study population. Next, for each individual, the 
energy-adjusted intake was calculated by adding the expected mean antioxidant 
intake of the study population to the residual derived from the regression analysis.
We estimated the risk of AMD associated with the dietary intake of antioxidant 
nutrients at baseline with Cox proportional hazards regression analysis. Intake 
of each nutrient was entered into the model either as a linear term per standard 
deviation (SD) or as a dummy variable representing 1 of the 3 highest quartiles. 
Quartiles were analyzed both as a categorical and as a continuous variable to test 
for trend. Quartiles and SDs were based on the distribution within the study sample. 
We adjusted for age, sex, body mass index, smoking status, pack-years of smoking, 
systolic blood pressure, serum total cholesterol, composite atherosclerosis score, 
and alcohol intake in all analyses. We additionally adjusted for intake of polyun-
saturated fat in the analysis of the fat-soluble vitamin E because of a reported asso-
ciation between this fat and AMD.19 Missing values of categorical variables were 
represented in the model by a missing indicator. For continuous variables, missing 
values were replaced by the mean or median of the study sample, depending on 
the distribution. Only the atherosclerosis composite score had more than 1% of the 
data missing (12.7%). To distinguish between the effect of antioxidants from food 
and from supplements, all analyses were repeated after exclusion of supplement 
users at baseline and also after adding supplement users to the highest quartile of 
dietary intake. Also, analyses were repeated after stratification for smoking status.
One of our aims was to study the regular dietary intake of the combination of 
nutrients that had been administered at a high dose in the AREDS.8 To secure large- 
enough groups with a relatively high or low intake of each of the 4 nutrients, we 
used the median intake per nutrient, based on the total sample, as the cutoff value. 
The high-intake group consisted of persons with an above median intake of each of 
the 4 nutrients. The low-intake group had a below-median intake of each nutrient, 
and all persons in between were considered the reference category.
Associations are presented as hazard ratios (HRs) with 95% confidence intervals 
(CIs). All analyses were performed using SPSS, release 11.0 (SPSS Inc, Chicago, Ill). 
results
Mean follow-up of participants was 8.0 years, with a range of 0.3 to 13.9 years 
(median, 10.6 years). During this period, 560 persons (13.4%) were diagnosed as 
having iAMD, the majority of whom had early AMD. Persons with early iAMD had 
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either large, soft drusen with pigment irregularities (n = 317) or indistinct drusen 
without (n = 124) or with (n = 77) pigment irregularities. Of the 42 persons with late 
iAMD, 14 had dry and 28 wet AMD. Twelve of them had AMD at the second follow-
up examination while 30 did so at the third follow-up. The incidence of AMD in the 
study sample was similar to the incidence in those with missing data on dietary 
intake who were not included in the sample (p = 0.60, adjusted for age and sex). 
Baseline characteristics of persons with iAMD as well as the remainder of the cohort 
are presented in Table 1. The mean age was 68.2 for the incident cases compared 
to 66.4 years for the remainder (p < 0.001). Persons with iAMD reported more pack-
years of cigarette smoking (p = 0.04) and had a higher serum high-density lipopro-
tein cholesterol level (p = 0.02). Other baseline characteristics were not different in 
the 2 groups.
Table 2 shows the mean daily dietary intake of the antioxidant nutrients in the 
study sample, adjusted for total energy intake. In Table 3, the risk of AMD in relation 
to nutrient intake is presented. A significant inverse association was observed for 
intake of vitamin E, iron, and zinc. After adjustment, a 1 SD increase in intake was 
table 1. Baseline characteristics of the study sample (n = 4170)*
Characteristics Incident AMD No AMD
(n = 560) (n = 3610) p-value†
Age, y 68.2 (7.1) 66.4 (7.2) < 0.001
Sex, female number (%) 321 (57.3) 2151 (59.6) 0.31
Body mass index‡ 26.3 (3.5) 26.4 (3.6) 0.66
Smoking status number (%)
 Never 183 (32.8) 1207 (33.6)
 Former 248 (44.4) 1561 (43.4) 0.36
 Current 127 (22.8) 825 (23.0) 0.55
Pack-years of smoking 18.5 (23.8) 16.4 (21.8) 0.04
Systolic blood pressure, mm Hg 138.9 (20.3) 137.1 (21.5) 0.76
Diastolic blood pressure, mm Hg 73.4 (10.7) 73.9 (11.0) 0.56
Total cholesterol, mmol/l 6.6 (1.2) 6.7 (1.2) 0.93
HDL cholesterol, mmol/l 1.4 (0.4) 1.4 (0.4) 0.02
Atherosclerosis composite score§ 2.7 (1.1) 2.5 (1.1) 0.21
Alcohol intake, g/d 10.8 (15.3) 10.6 (15.3) 0.20
Number of antioxidant supplement users (%) 60 (10.7) 499 (13.8) 0.09
* Data are expressed as mean (SD) unless otherwise indicated
† Adjusted for age and sex
‡ Body mass index was calculated as weight in kilograms divided by the square of height in meters
§ Information on the atherosclerosis composite score is presented in the “Methods” section of the text
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associated with a reduced risk of AMD of 8% (95% CI, 0%–16%) for vitamin E and 9% 
(95% CI, 2%-17%) for zinc. 
The risk of AMD by quartiles of nutrient intake is presented in the Figure. The test 
for trend for both vitamin E (p = 0.04) and zinc (p = 0.06) intake indicated a dose-
response relationship between vitamin E and zinc intake and reduced risk of AMD.
Table 4 presents the impact of the combined dietary intake of the 4 antioxidants 
that were studied in AREDS.8 Intake of these nutrients in the present study was 
considerably lower than the high-dose supplements used in the AREDS. An above-
median intake of beta carotene, vitamins C and E, and zinc, compared with a below-
median intake of at least 1 of these nutrients, was associated with a reduced risk of 
AMD (HR, 0.65; 95% CI, 0.46-0.92) adjusted for all potential confounders. In persons 
with a below-median intake of all 4 nutrients, the risk of AMD was increased but not 
significantly so (HR 1.20; 95% CI, 0.92-1.56).
Exclusion of the 559 participants who used antioxidant supplements at baseline 
did not substantially alter the risk estimates (Table 5). In addition, adding supple-
ment users to the highest quartile of dietary intake did not change the results (HR, 
adjusted for the same factors as in Table 5, 0.77; 95% CI, 0.61-0.98). Stratification 
for smoking status did not substantially change point estimates but widened the 
confidence intervals (Table 5).
table 3. Risk of aging macula disorder per standard deviation (SD) increase in dietary intake of 
antioxidant nutrients.
Nutrients
 
Mean dietary intake (SD), 
mg/d
Adjusted Hazard Ratio per 1-SD 
Increase (95% confidence interval)*
Carotenoids
 Alpha carotene   1.12 (0.84) 0.99 (0.94 - 1.06)
 Beta carotene   3.84 (2.23) 1.00 (0.94 - 1.06)
 Beta cryptoxanthin   0.29 (0.22) 1.01 (0.92 - 1.10)
 Lutein/Zeaxanthin   2.37 (1.08) 1.01 (0.93 - 1.09)
 Lycopene   0.80 (0.80) 1.01 (0.97 - 1.04)
Vitamins
 Vitamin A (retinol equivalents)   0.82 (0.35) 0.95 (0.86 - 1.05)
 Vitamin C 120.20 (52.49) 1.02 (0.94 - 1.10)
 Vitamin E  13.42 (5.19) 0.92 (0.84 - 1.00)
Trace elements
 Iron  12.04 (2.16) 0.95 (0.86 - 1.04)
 Zinc   9.67 (2.01) 0.91 (0.83 - 0.98)
*  Adjusted for age, sex, body-mass index, smoking status, pack-years of smoking, systolic blood 
pressure, atherosclerosis composite score, serum total cholesterol, and alcohol intake.
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figure: Hazard ratios for incident aging macula disorder by quartile of energy-adjusted dietary intake of 
antioxidant carotenoids
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Error bars indicate 95% confidence intervals. Adjusted for age, sex, body mass index, smoking status, 
pack-years of smoking, systolic blood pressure, atherosclerosis composite score, serum total cholesterol, 
and alcohol intake. The lowest quartile was considered the reference group. For each nutrient, the p-value 
of the test for trend is given.
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table 4. Risk of aging macula disorder by category of combined intake of 4 predefined antioxidant 
nutrients (vitamins C and E, beta carotene, and zinc).
Category of dietary intake*
Low
n = 466
Middle
n = 3270
High
n = 434
Cases (%) 76 (16.3)  442 (13.5)  42 (9.7)
Hazard ratio (95%  
confidence interval) 
 Unadjusted 1.31 (1.03 - 1.67) 1.00 0.65 (0.48 - 0.89)
 Age- and sex-adjusted 1.23 (0.97 - 1.58) 1.00 0.68 (0.49 - 0.93)
 Fully adjusted† 1.20 (0.92 - 1.56) 1.00 0.65 (0.46 - 0.92)
*  Categories were defined by using the median energy-adjusted intake per nutrient as a cutoff value 
and classifying above-median intake of all nutrients as high intake and below-median intake of all 
nutrients as low intake. Cutoff values were 114 mg for vitamin C, 13 mg for vitamin E, 3.6 mg for beta 
carotene, and 9.6 mg for zinc
†  Adjusted for age, sex, body-mass index, smoking status, pack-years of smoking, systolic blood 
pressure, atherosclerosis composite score, serum total cholesterol, and alcohol intake
table 5. Risk of aging macula disorder by category of combined intake of 4 predefined antioxidant 
nutrients (vitamins C and E, beta carotene, and zinc), excluding supplement users and stratified by 
smoking status.
Categories of intake*
Low Middle High
Excluding supplement users n = 419 n = 2816 n = 376
 Cases (%) 67 (16.0) 396 (14.1) 37 (9.8
 HR (95% CI)† 1.11 (0.84 - 1.46) 1.00 0.62 (0.43 - 0.90)
Smoking Status
Never n = 128 n = 1096 n = 160
 Cases (%) 17 (13.3) 144 (13.3) 16 (10.0)
 HR (95% CI)‡ 0.85 (0.48 - 1.50) 1.00 0.74 (0.42 - 1.31)
Former n = 182 n = 1434 n = 193
 Cases (%) 31 (17.0) 199 (13.9) 18 (9.3)
 HR (95% CI)‡ 1.26 (0.84 - 1.99) 1.00 0.58 (0.34 - 0.98)
Current n = 154 n = 727 n = 77
 Cases (%) 28 (18.2) 97 (13.3) 8 (10.4)
 HR (95% CI)‡ 1.44 (0.93 - 2.22) 1.00 0.65 (0.30 - 1.40)
Abbreviations: CI indicates confidence interval; HR, hazard ratio
*  Categories were defined by using the median energy-adjusted intake per nutrient as a cutoff value 
and classifying above-median intake of all nutrients as high intake and below-median intake of all 
nutrients as low intake. Cutoff values were 114 mg for vitamin C, 13 mg for vitamin E, 3.6 mg for beta 
carotene and 9.6 mg for zinc
†  Adjusted for age, sex, body-mass index, smoking status, pack-years of smoking, systolic blood 
pressure, atherosclerosis composite score, serum total cholesterol, and alcohol intake
‡  Adjusted for all of the above except smoking status and pack-years of smoking
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discussion
We found that high dietary intake of vitamin E and zinc was associated with a lower 
risk of iAMD. An above-median intake of the combination of vitamins C and E, beta 
carotene, and zinc was associated with a 35% lower risk of incident AMD. 
The strengths of our study were the prospective design, the population-based 
cohort, the detailed and similar grading of AMD at baseline and follow-up, and the 
long follow-up. Potential weaknesses were, as in all observational studies, selec-
tion bias, information bias and confounding. Selective nonresponse was unlikely 
because non-participants did not differ from participants in the dietary intake of 
antioxidants. Bias in the diagnosis of AMD was minimized by the masked grading of 
photographs by persons unaware of the antioxidant nutrient status. Misclassification 
potentially could result from the use of only 1 food questionnaire at baseline, but 
such misclassification would be nondifferential and, therefore, more likely to under-
estimate the true associations. The questionnaire was not validated for all nutrients 
included in the current analysis; e.g., specific carotenoids and vitamin E. However, 
for other nutrients, the validity of the questionnaire was shown to be moderate to 
good. The adjusted Pearson correlation coefficient for vitamin A (including retinol 
and beta carotene) was 0.48; for vitamin C, 0.64; for iron, 0.42; and for zinc, 0.51.13,14 
For vegetables, the correlation was 0.39, and for fruit 0.60. Since alpha and beta 
carotene, and lutein intake are well correlated with total vegetable intake, we pre-
sumed equal validity. The same held for the correlation between beta cryptoxanthin 
and vitamin C. It is possible that other factors can explain the reported associations. 
Although we adjusted for known confounders, such as smoking and atherosclero-
sis, unknown factors associated with a healthy diet still may have played a role.
The median nutrient intake used as a cutoff value was at or above the RDA, so the 
majority of our population presumably consumed a healthy diet. A larger risk reduc-
tion was observed for dietary intake above the RDA for all 4 micronutrients than for 
individual micronutrients. To ensure that diet was the only source of antioxidant 
intake, we repeated the analysis excluding persons using antioxidant supplements 
at baseline (13.4%) and also investigated the combined effect of antioxidants from 
food and from supplements. This resulted in similar risk estimates. The independent 
association between antioxidant supplements and AMD could not be examined 
because of the relatively small number of antioxidant supplement users in our 
population and the lack of data on duration and dosage of use. 
Recent data suggest that oxidative protein modifications may play a critical role in 
the formation of drusen.20 This implies that antioxidants may have their strongest 
effect at the initiation of the disease. We studied a cohort that was free of clinical 
signs of early AMD at baseline, and our incident cases were primarily affected by 
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early AMD. Early AMD, however, is a strong predictor of late AMD.10, 12 Exclusion of 
the 42 persons with late iAMD did not change the results. We therefore conclude 
that dietary antioxidants may delay the development of early and, possibly, of AMD 
in general. 
Different antioxidants may act synergistically;3 therefore, we studied the combined 
effect of nutrients and used the combination previously investigated in AREDS.8 We 
observed a dose-response relationship with a mean intake of beta carotene, vita-
mins C and E, and zinc as reference. Persons with an above-median intake of these 
nutrients may be different in other aspects. This residual confounding is inherent to 
an observational study and can only be dealt with in a randomized trial. However, 
experimental studies with a randomized change in food consumption are difficult 
to perform.
Previous studies have shown variable degrees of protection against AMD by differ-
ent antioxidants. Dietary intake of vitamin E was not associated with AMD in 1 case-
control study in persons with wet late AMD4 but showed an inverse association with 
large drusen in a population-based study.7 A high intake of lutein and zeaxanthin 
was associated with a 40% lower risk of late AMD in 1 study4 but history of intake 
of these 2 nutrients was not associated in another study.7 A randomized controlled 
trial of vitamin E supplementation did not show an effect on the incidence of early 
AMD after 4 years of follow-up.21 An inverse association between zinc intake and 
both prevalent and incident early AMD was reported in 1 population-based cohort 
study22 but could not be confirmed in another similar study23, 24 or in a pooled study 
in which late AMD and visual acuity data were obtained by self-report.25 In con-
trast the aforementioned studies, our results were based on long-term follow-up 
of a large, population-based cohort with thorough baseline assessment of dietary 
intake. 
Recently, a meta-analysis of 19 clinical trials including AREDS showed that high-dos-
age (≥ 400 IU/day) vitamin E supplementation may increase all-cause mortality.26 This 
finding would challenge recommendations for supplement use.8 It should be noted 
that most trials were performed in patients with chronic diseases, in contrast with 
the general population in our study sample. The mean amount of vitamin E con-
sumed in diet in the highest quartile of our cohort (20.2 mg/d [30 IU/d]) was still 
considerably lower than high-dose supplementation, and the bioavailability of 
dietary antioxidants may be different from that in supplements. Dietary replace-
ment also may be less expensive than supplement use.
This study suggests that the risk of AMD can be modified by diet; in particular, by 
dietary vitamin E and zinc. A higher intake of vitamin E can be achieved by con-
sumption of whole grains, vegetable oil, eggs, and nuts. High concentrations of 
zinc can be found in meat, poultry, fish, whole grains, and dairy products. Carrots, 
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kale, and spinach are the main suppliers of beta carotene, while vitamin C is found 
in citrus fruits, and juices, green peppers, broccoli, and potatoes. Based on this 
study, foods high in these nutrients appear to be more important than nutritional 
supplements. Until more definitive data become available, this information may be 
useful to persons with signs of early AMD or to those with a strong family history 
of AMD.27 Although in need of confirmation, our observational data suggest that a 
high intake of specific antioxidants from a regular diet may delay the development 
of AMD.
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C-reactive protein and risk of 
aging macula disorder
The Rotterdam Study
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ABstrAct 
context: Recently some clinic-based studies found an association between serum 
C-reactive Protein (CRP) levels and aging macula disorder (AMD). 
objective: To examine whether CRP levels are a risk factor for AMD in a general 
population.
methods: We examined serum high sensitivity CRP (HsCRP) levels in 4914 partici-
pants of the population-based Rotterdam Study at risk for AMD. After a mean fol-
low-up time of 7.7 years, 561 cases of early and 97 cases of late incident AMD (iAMD) 
were identified. We used Cox proportional hazards regression analysis to estimate 
hazard ratios and corresponding 95% confidence intervals (CIs).
results: After adjustment for age and sex, hazard ratios for early iAMD were 1.11 
(95% CI 1.02-1.21) per standard deviation increase of HsCRP and for late iAMD 1.28 
(95% CI 1.02-1.60). Hazard ratios for early iAMD also increased per quartile increase 
of HsCRP level: 2nd quartile: 1.19 (95% CI 0.94-1.52), 3rd quartile: 1.29 (95% CI 1.01-
1.64), 4th quartile: 1.33 (95% CI 1.05-1.70). The risk of late iAMD was also higher in 
all-upper quartiles of HsCRP. 
conclusion: Elevated baseline levels of HsCRP were associated with the develop-
ment of early and late AMD in this large population-based cohort.
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introduction 
Since its first description of age-related macular degeneration in senile persons1, 
at least 20 different names have been given to this disease according to the views 
about its pathogenesis at the subsequent times. We now prefer the name “aging 
macula disorder” (AMD)2 for the following reasons. Age-related does not differenti-
ate between juvenile macular disease and that associated with old age, it is open for 
debate if and when early or late AMD becomes a disease, and patients do not want 
to be associated with senility or degeneration. 
AMD is a condition affecting the center of the retina in the elderly. Late AMD is 
the main cause of incurable vision loss in the Western world3-5 and its prevalence 
is estimated to double by 2020.6 Its pathogenesis is still not clear although some 
modifiable risk factors as smoking and hypertension have been found.7 
Local inflammatory and immune-mediated events play a role in the development of 
drusen, white subretinal extracellular deposits that are a hallmark of AMD.8-10 Direct 
analysis by liquid chromatography and immunocytochemical analyses confirmed 
that drusen contain proteins associated with inflammation, such as complement 
components, C-reactive protein (CRP), fibrinogen and vitronectin.11, 12 A number of 
these proteins appears to be locally produced by damaged RPE cells.13 Also inflam-
matory cells such as multinucleated giant cells and leukocytes were described 
in the choroid of eyes with late AMD and in excised choroidal neovascular mem-
branes.14-17 
Chronic inflammation seems to be an etiological factor in the development of AMD. 
Several studies have investigated this possible association from different perspec-
tives. A mouse model with defects in macrophage mobilization demonstrated many 
pathological features of AMD, suggesting that macrophage dysfunction plays a role 
in AMD.18 Data from a case-control study found an association between antibod-
ies against Chlamydia pneumoniae and wet (neovascular) late AMD.19 In addition 
a modest association was found between pigmentary abnormalities and wet late 
AMD and emphysema, and gout was associated with the incidence of dry late AMD.20 
Recently a strong association between the Y402H single nucleotide polymorphism 
(SNP) in the complement factor H (CFH) gene and AMD was found in three clinic-
based case-control studies21-23 and in a longitudinal population-based one.24 CFH 
plays an essential role in the inhibition of the alternative complement pathway and 
abnormal regulation of this pathway leads to an increased inflammatory state. 
CRP is a non-specific marker of systemic inflammation. It activates the classical route 
of complement activation directly and via cytokines through Fc-receptor binding 
by antibodies, which enhances the inflammatory respons.12 Two clinic-based cross-
sectional studies25, 26 and a longitudinal clinical one by similar authors27 reported an 
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association between CRP and AMD, supporting the inflammatory pathogenesis of 
AMD. We investigated whether baseline high sensitivity CRP (HsCRP) serum levels 
were also a risk factor for AMD in the general population.
methods
Population
The Rotterdam Study is a prospective, population-based cohort study investigat-
ing the incidence and determinants of chronic disabling diseases in the elderly. All 
inhabitants aged 55 years or older living in a suburb of Rotterdam, the Netherlands 
were invited.28 Of the 10,275 eligible individuals, 7983 (78%) participated. The oph-
thalmologic part of the study started after screening of the participants had begun, 
leading to 6780 (also 78% response) ophthalmic participants. The tenets of the 
Declaration of Helsinki were followed and the appropriate medical ethics commit-
tees approved of the study. All participants signed an informed consent and gave 
permission to retrieve information from medical records. Baseline examinations, 
including a home interview and physical examinations at the research center took 
place from 1990 till 1993 and were followed by three examinations from 1993 to 
1994 (response rate 88%), from 1997 to 1999 (response rate 80%) and from 2000 till 
the end of 2004 (response rate 74%). 
Measurement of high sensitivity C-reactive protein
At baseline nonfasting blood was collected and processed by standard techniques, 
and stored at -20°C.29 In 2003 and 2004, serum levels of HsCRP were determined 
by Rate Near Infrared Particle Immunoassay method (IMMAGE® high sensitive CRP, 
Beckman Coulter, USA). This system measures concentrations ranging from 0.2 to 
1140 mg/L, with a within-run precision < 5.0%, a total precision < 7.5%, and a reli-
ability coefficient of 0.995. In a random sample of the study (n = 29), we compared 
HsCRP measurements from baseline blood from the same participants stored at 
-20°C and -80°C. The correlation between these measurements was high (Spearman 
correlation 0.99; p < 0.001), although HsCRP levels were somewhat lower in blood 
stored at -20°C (mean difference, -0.5097; 95% CI, -1.637 to 0.618). This difference 
was not statistically significant. Because we used for all our analyses these -20°C 
stored samples, we do not expect that this affected our point estimates. The HsCRP 
distribution was skewed. Outliers (values > 3 standard deviations (SD) of the popu-
lation distribution) of the logarithmically transformed HsCRP values were excluded 
from the analyses, since they may indicate the presence of an acute inflammatory 
disease.29
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AMD definition
For the diagnosis of AMD, 35° color pictures were taken of the macular area of each 
eye (Topcon TRV-50VT fundus camera, Topcon Corporation, Tokyo, Japan) after dila-
tation of the pupils with tropicamide 0.5% and phenylephrine 5%. These transparen-
cies, and in the last follow-up digitized images, were graded with 12.5x magnification 
according to the International Classification and Grading System30 by the same two 
trained professionals grading AMD from baseline on, who were masked for all other 
determinants.31, 32 We deviated from this system by changing the name age-related 
maculopathy in AMD. Also by categorizing the range of AMD fundus signs into five 
mutually exclusive stages 0 to 4 that had an increasing risk of late AMD.32 No AMD 
was defined as stage 0, no signs of AMD at all or only hard drusen (< 63 μm); stage 
1 included soft distinct drusen (≥ 63 μm), or pigmentary abnormalities. Because 
for our analyses we wanted to have a clear separation between participants with 
no or early AMD and quite some participants with only one or two soft distinct 
drusen were classified as stage 1, we considered stage 1 as no AMD in the present 
analyses. For these analyses we included as early AMD stage 2, soft indistinct drusen 
(≥ 125 μm) or reticular drusen only or soft distinct drusen (≥ 63 μm) with pigmentary 
abnormalities, and stage 3, soft indistinct drusen (≥ 125 μm) or reticular drusen with 
pigmentary abnormalities. Stage 4 was similar to late AMD, usually associated with 
severe visual loss.32 Late AMD was subdivided in dry (geographic atrophy) and wet 
(neovascular) AMD. A person was classified according to the highest stage of AMD 
in either eye and in case both dry and wet AMD were present, as wet AMD. Early 
incident AMD (iAMD) was defined as any sign of early AMD in at least one eye during 
follow-up among participants with no AMD at baseline in either eye. Persons who 
were free of late AMD at baseline in both eyes and developed it in at least one eye 
during follow-up were classified as having late iAMD. 
Population for analysis
At baseline, gradable fundus transparencies of 6418 participants were available, of 
whom 476 (7.4%) had early and 106 (1.7%) late AMD. This resulted in 5836 persons 
at risk for early or late AMD and 6312 persons at risk for late AMD only. Of the 6312 
participants at risk for early and late iAMD, 4914 (77.9% of those at risk) participated 
in at least one follow-up examination. Our study population consisted of 4624 
(73.3%) participants from these in whom we had baseline HsCRP measurements. 
HsCRP levels were missing from persons who did not visit the research center or 
refused blood sampling and from participants of whom no blood was available due 
to random logistic reasons. We excluded 20 (0.43%) persons at risk of any AMD with 
outliers in HsCRP levels, leaving 4604 participants as our population for analysis. 
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Assessment of confounders
Information on all potential confounders was collected at baseline. During a home 
interview, trained research assistants asked participants for their smoking habits. 
Smoking was categorized as current, past or never smoker. Anthropometric mea-
surements were obtained at the research center. Body mass index was calculated 
as weight in kilograms divided by height in meters squared (kg/m2). Systolic and 
diastolic blood pressures were measured twice at the right brachial artery with a 
random zero sphygmomanometer in a sitting position. The average of these two 
measurements was used to determine blood pressure levels. Non-fasting blood 
samples were obtained from all participants. Serum total cholesterol and high-den-
sity lipoprotein (HDL) levels were measured by an automated enzymatic procedure. 
Diabetes mellitus was considered to be present when persons currently used blood-
glucose lowering medication, or had a non-fasting or post-load glucose level above 
11.0 mmol/L.
Data analysis
We investigated associations between HsCRP levels and early or late iAMD using a 
Cox proportional hazards model to compute hazard ratios (HRs) and corresponding 
95% confidence intervals (CIs). Follow-up time in years was used as time-axis of the 
model. Hazard ratios take time to event into account, and can be interpreted as 
relative risks. Linear trends were analyzed in which the regression coefficient was 
expressed per SD increase and quartiles were analyzed both continuously and as 
categorical variables. All analyses were initially adjusted for age and sex. To check 
whether associations could be attributed to confounding, analyses were repeated 
with possible confounders added to the model (smoking, body mass index, dia-
stolic and systolic blood pressure, diabetes mellitus, total and HDL cholesterol). All 
analyses were carried out using SPSS 11.0.
results
Baseline characteristics of participants free of any AMD at baseline and follow-up, 
and persons at risk for early and late iAMD are shown in Table 1. Persons with miss-
ing HsCRP values were on average older, included more women, were more often 
resident in a nursing home and had lower HDL levels. Follow-up of participants was 
on average 7.7 years (median 10.4 years; range 0.3 to 13.9 years). During this period, 
658 persons were diagnosed with any iAMD of which 561 persons developed early 
and 97 late iAMD. Among all participants with iAMD, HsCRP levels ranged from 0.20 
to 33.60 (mean 2.67 mg/L, SD 3.22); in those with early iAMD these ranged from 
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0.20 to 31.50 mg/L (mean 2.69 mg/L, SD 3.08) and in those with late iAMD from 0.20 
to 16.80 mg/L (mean 3.04 mg/L, SD 3.18).
The risk of early iAMD increased per SD rise in HsCRP level, adjusted for age and sex, 
(HR, 1.11; 95% CI 1.02-1.21) also after multivariate adjustment (HR, 1.11; 95% CI 1.02-
1.22). Table 2 shows that, the risk of early iAMD also rose with each higher quartile 
of HsCRP. Additional adjustment for cardiovascular covariates did not substantially 
change this.
The risk of late iAMD rose per SD increase in HsCRP (HR, 1.31; 95% CI 1.06-1.61) as 
well as after additional adjustments (HR, 1.28; 95% CI 1.02-1.60). Table 3 shows that 
table 1: Baseline characteristics of the 4604 participants of our population for analysis.
Variable No AMD
n = 3946
Early AMD
n = 561
Late AMD
n = 97
Age, years 66.7 (7.7)* 68.2 (7.6) 72.0 (6.5)
Sex, female (%) 2315 (58.7) 315 (56.1) 55 (56.7)
Smoking status (%)
 Never 1324 (33.8) 186 (33.6) 26 (27.7)
 Former 1705 (43.6) 240 (43.4) 43 (45.7)
 Current 886 (22.6) 127 (23.0) 25 (26.6)
Diabetes Mellitus (%) 362 (9.2) 39 (7.0) 8 (8.2)
Body Mass Index, kg/m  
2 26.4 (3.7) 26.2 (3.5) 26.1 (3.3)
Systolic blood pressure, mm Hg 137.5 (21.7) 138.9 (20.7) 139.1 (19.5)
Diastolic blood pressure, mm Hg 74.0 (11.1) 73.4 (11.2) 71.8 (11.1)
Total cholesterol, mmol/L 6.7 (1.2) 6.6 (1.2) 6.6 (1.1)
HDL cholesterol, mmol/L 1.3 (0.4) 1.4 (0.4) 1.3 (0.4)
* Means and standard deviations between brackets, unless otherwise indicated 
table 2: Risk of early iAMD for quartiles of baseline HsCRP levels.
Quartiles
(range) 
n
(cases)
Hazard ratio 
(95%CI)*
Hazard ratio 
(95%CI)**
1st
(≤ 0.83)
1135
(123)
1.00 
(reference)
1.00
(reference)
2nd
(0.84 - 1.72)
1132
(146)
1.19
(0.94 - 1.52)
1.26 
(0.99 - 1.61)
3rd
(1.73 - 3.25)
1116
(147)
1.29 
(1.01 - 1.64)
1.35 
(1.05 - 1.74)
4th
(≥ 3.26)
1124
(145)
1.33 
(1.05 - 1.70)
1.40 
(1.08 - 1.81)
p-trend 4507
(561)
0.02 0.01
* Adjusted for age and sex
**  Additionally adjusted for smoking, body mass index, diabetes mellitus, systolic and diastolic blood 
pressure, total cholesterol and HDL cholesterol
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the risk of late iAMD was higher in all-upper quartiles of HsCRP. However, this only 
reached statistical significance in the third quartile of the fully adjusted model. The 
results adjusted for age and sex follow a dose-response pattern, but after additional 
adjustments this effect was lost probably due to a more limited sample size for late 
AMD.
discussion
In this population-based cohort we confirmed data from three clinic-based 
studies25-27, that baseline HsCRP levels were associated with both early and late 
iAMD, with the highest risks in the latter one. This is another support that inflam-
mation is one of the mechanisms involved in the pathogenesis of AMD also in the 
general population.24
Injury to the RPE and possible to the choroid caused by smoking, low antioxidant- 
intake, light toxicity and obesity may induce AMD through a state of chronic inflam-
mation.2, 25 Choroidal dendritic cells, which are found to be associated with drusen, 
respond to locally damaged RPE cells and migrate to the site of tissue damage.10 
Dendritic cells trigger immune-mediated pathways. In persons with AMD the down-
regulation of the immune response may be hampered resulting in a state of chronic 
inflammation of the RPE and damage to the underlying Bruch’s membrane leading 
to progression of AMD.10
Evidence is accumulating that inflammatory and immune-associated pathways also 
play a role in other degenerative diseases associated with advancing age, such as 
table 3: Risk of late iAMD for quartiles of baseline HsCRP levels.
Quartiles
(range)
n Hazard ratio 
(95%CI)*
Hazard ratio 
(95%CI)**
1st
(≤ 0.83)
1028
(16)
1.00
(reference)
1.00
(reference)
2nd
(0.84 - 1.72)
1010
(24)
1.34
(0.71 - 2.54)
1.35 
(0.70 - 2.58)
3rd
(1.73 - 3.22)
999
(30)
1.90
(1.03 - 3.49)
1.96 
(1.04 - 3.69)
4th
(≥ 3.23)
1006
(27)
1.95 
(1.05 - 3.63)
1.79 
(0.92 - 3.48)
p-trend 4043
(97)
0.02 0.05
* Adjusted for age and sex
**  Additionally adjusted for smoking, body mass index, diabetes mellitus, systolic and diastolic blood 
pressure, total cholesterol and HDL cholesterol
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atherosclerosis and Alzheimer’s disease.33-36 Drusen components were also found in 
atherosclerotic plaques and deposits in Alzheimer’s disease 12 and AMD, atheroscle-
rosis and Alzheimer’s disease may partly share a similar inflammatory pathogen-
esis.
Differential misclassification is unlikely in our study, because AMD graders were 
masked for HsCRP status and HsCRP data were collected, without knowledge of 
AMD status. Persons who refused to participate or were lost to follow-up were older 
and less healthy.32 If persons with higher HsCRP levels and AMD would selectively 
not have participated, selection bias would have been introduced. We think this is 
unlikely because people were unaware of their HsCRP level, and only in late iAMD 
cases would they be aware of symptoms. We measured HsCRP levels only once. This 
should not be a major problem because HsCRP has a long half-life of approximately 
19 hours37 and concentrations appear to be fairly stable over at least 5 years in most 
individuals.38, 39 Furthermore there is no circadian variation and there is no evidence 
for seasonal variations in HsCRP.38, 40-42 
Several large-scale prospective studies have demonstrated that elevated levels of 
HsCRP were an independent predictor of future cardiovascular events in healthy indi-
viduals.43, 44 In addition to predicting cardiovascular death and myocardial infarction, 
serum HsCRP is also a predictor of stroke and the development of peripheral arterial 
disease.45 Although not yet proven it is hypothesized that CRP directly promotes 
atherosclerosis and therefore functions as a mediator in the process.45-49 C-reactive 
protein-lowering treatments, for example by the use of statins or improvement of 
lifestyles, were associated with reduced cardiovascular risks.39, 45, 50, 51 
Atherosclerosis is a known risk factor for AMD, most likely through a decreased 
choroidal blood flow directly or indirectly impairing the functioning of the RPE.52, 53 
Atherosclerosis is associated with elevated HsCRP levels which could explain the 
higher risk of AMD.36 After correction for cardiovascular risk factors the linear trend 
analysis for early iAMD remained significant, but with late iAMD this became bor-
derline significant. Statistical power due to the lower number of late iAMD cases 
could have caused the loss of significance, especially since the hazard ratio was still 
elevated. 
CFH is an essential regulator in the complement system. It inactivates C3b and func-
tions therefore as an activation inhibitor of the alternative complement pathway.54, 55 
Due to the CFH Y402H SNP21-24 complement activation is less suppressed, leading to 
an increased inflammatory reaction. T his SNP is located in a region that contains 
the binding sites for heparin and CRP. CFH binds to CRP which may help inhibit the 
CRP-dependent alternative pathway activation induced by damaged tissue.54 CFH 
tends to prevent the assembly of complement complex in the arterial intima.56 It 
has been suggested that allele-specific changes in activities of the binding sites for 
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heparin and CRP modify the protective action of CFH.22 It is possible that comple-
ment-related damage to choroidal vessel walls may lead to wet AMD.22, 23
One wonders if reduction of CRP levels would lower the risk of AMD. A substance 
that can selectively inhibit CRP synthesis has not yet been developed. High body 
mass index as well as smoking increase CRP levels and moderate alcohol intake, 
diets with a low glycemic index, statins and multivitamins reduce them.46, 57 Addi-
tional correction for smoking and obesity, also associated with a higher risk of AMD, 
did not change our point estimates. Nevertheless, reducing both might have a pro-
tective effect. 
As mentioned, two clinical cross-sectional studies and a longitudinal one found 
an association between CRP and AMD,25-27 while a population-based longitudinal 
study58 and a population-based cross-sectional study could not confirm this.59 How-
ever these last two studies included fewer cases, especially with late AMD. It has 
been suggested that differences in results could be contributed to the possibility 
that inflammation may play a larger role in the pathogenesis of progression to late 
AMD instead of early AMD.58 However, in our present study we did not only find 
an association between HsCRP levels and late iAMD, but also with early iAMD. This 
is in line with the known progression over the years from stage 0 to stage 4 AMD 
and supports the inflammatory pathogenesis of both early and late AMD. Finally, 
clinic-based and cross-sectional studies are more prone to selection bias and thus 
we think that confirmation by a longitudinal population-based one is important. 
In conclusion, persons with a relatively high HsCRP level (> 1.73 mg/L) within the 
normal range, have a significant higher risk of early and late AMD. We consider 
HsCRP a potential useful biological marker in profiling the risk of AMD for individual 
persons.
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ABstrAct
objective: To investigate still controversial associations between overall or specific 
alcohol consumption and aging macula disorder (AMD) in a general population.
methods: Alcohol consumption and risk of early or late incident AMD (iAMD) were 
examined in all participants in the prospective population-based Rotterdam study 
at risk for AMD of whom we had complete data on alcohol consumption (n = 4229). 
AMD was graded according to the International Classification and Grading System 
by the same two trained professionals, who were masked for all other determinants. 
We used Cox proportional hazards regression analysis to estimate hazard ratios and 
corresponding 95% confidence intervals (CIs).
results: During an average follow-up period of 8 years, 600 cases of iAMD were 
identified, of whom 519 had early and 81 late AMD. After correction for age, sex, 
smoking, CFH genotype status and other potential confounders, we did not find an 
association between overall or specific alcohol consumption and risk of early, late 
dry or late wet iAMD. 
conclusion: Our findings suggest that overall and specific alcohol consumption is 
not a risk factor for early or late AMD. 
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introduction
Aging macula disorder (AMD), as we now prefer to call age-related macular degen-
eration,1 constitutes due to limited treatment options a major burden on the quality 
of life of the Western population.2-4 Identification of modifiable risk factors thus is 
of great importance. Alcohol consumption is one such factor. Alcohol use is quite 
common in the Netherlands, 80% of the Dutch population older than twelve years 
consumes alcohol, and 10% is classified as a heavy drinker, consuming six or more 
glasses of alcohol a day at least once a week.5
Moderate alcohol consumption is associated with a decreased risk of cardiovascular 
disease.6-8 Increasing evidence that AMD is associated with vascular disease,9 thus 
would point to an inverse association between moderate alcohol intake and AMD. 
On the other hand alcohol is hypothesized to increase oxidative stress or to influ-
ence mechanisms that protect against oxidative damage.10 
Two cross-sectional and three incidence studies found an association between 
alcohol consumption and AMD.11-15 Conversely, four different cross-sectional and 
incidence studies could not confirm these results.16-19 These inconsistent findings 
could be attributed to differences in study design, numbers of cases, ethnicity, or 
in the way AMD was diagnosed. In addition, studies resulting in positive associa-
tions between alcohol intake and AMD could not clarify which type of beverage is 
important. Of all prospective studies investigating this association, the Beaver Dam 
Study is the only one comparable to our study.14 Both are large population-based 
studies using standardized and similar grading for AMD, and were able to perform 
beverage-specific analyses. Beer consumption is over 10% higher in the Beaver 
Dam Study compared to our study, but wine consumption is approximately 45% 
higher in Rotterdam. This enabled us to investigate the association between wine 
consumption and incident AMD. Thus we studied in this population-based cohort 
the risk of early or late AMD according to consumption of different levels and types 
of alcohol. 
methods
Population
The Rotterdam Study is a prospective, population-based cohort study of cardiovas-
cular-, locomotor-, neurologic- and ophthalmologic diseases in the elderly.20 
In summary, all inhabitants aged 55 years or older living in Ommoord, a suburb of 
Rotterdam, the Netherlands were invited to participate in the study. Of the 10,275 
eligible individuals, 7983 participated (78%). The ophthalmologic part of the study 
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started after screening of the participants had begun, leading to 6780 ophthalmic 
participants, also with 78% response rate. The Rotterdam Study was approved 
by the medical ethics committee of the Erasmus University and written informed 
consent was obtained from all participants. Baseline examinations, including a 
standardized home interview and physical examination at the research center took 
place between March 1990 and July 1993. Three follow-up examinations took place 
from September 1993 to the end of 1994, from 1997 to 1999 and from 2000 to the 
end of 2004. 
AMD definition
In order to diagnose AMD, 35° color photographs were taken of the macular area 
of each eye (Topcon TRV-50VT fundus camera, Topcon Corporation, Tokyo, Japan) 
after dilatation of the pupils with tropicamide 0.5% and phenylephrine 5%. Fundus 
transparencies and digitized images from the last follow-up examination21, 22 were 
graded with 12.5x magnification according to the International Classification and 
Grading System for AMD.23 Two well-trained graders, each having 11 years of experi-
ence, graded the fundus images masked for all other participant characteristics. The 
grading procedures and definitions, as well as the graders, were identical at baseline 
and at follow-up. We modified the nomenclature from age-related maculopathy23 
into AMD, dividing it in early and late AMD. Late AMD in the present manuscript 
is similar to AMD in that classification system23 and is divided in dry (geographic 
atrophy) and wet (neovascular) AMD.
Next AMD was classified into five mutually exclusive stages 0 to 4 that had an 
increasing risk of late AMD.24 No AMD was defined as stage 0, no signs of AMD at 
all or only small hard drusen (< 63 μm), and stage 1 soft distinct drusen (≥ 63 μm), 
or pigmentary abnormalities. Because many participants with only one large druse 
or one hyperpigmentation in this system are classified as stage 1 and because we 
wanted to separate participants with marked AMD from those with only limited 
signs, we considered stage 1 as no AMD in the present analyses. Early AMD included 
stage 2, soft indistinct drusen (≥ 125 μm) or reticular drusen only or soft distinct 
drusen (≥ 63 μm) with pigmentary abnormalities, and stage 3, soft indistinct drusen 
(≥ 125 μm) or reticular drusen with pigmentary abnormalities. Late AMD was similar 
to stage 4. Dry AMD was defined as any sharply demarcated round or oval area of 
apparent absence of the retinal pigment epithelium (RPE), larger than 175 µm, with 
visible choroidal vessels, and no wet AMD. Wet AMD was defined as the presence 
of a serous or hemorrhagic detachment of the RPE and/or a subretinal neovascular 
membrane and/or subretinal hemorrhage, and/or periretinal fibrous scar. A person 
was classified according to the highest stage of AMD in either eye, in case of mixed 
dry and wet classifying wet higher than dry AMD. Early incident AMD (iAMD) was 
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defined as any sign of early AMD in at least one eye during follow-up among par-
ticipants with no AMD at baseline in either eye. Persons who were free of late AMD 
at baseline in both eyes and developed it in at least one eye during follow-up were 
classified as having late iAMD. Lesions that were considered to be the result of gen-
eralized disease, such as diabetic retinopathy, chorioretinitis, high myopia, trauma, 
congenital diseases, or photocoagulation for reasons other than for wet AMD, were 
excluded from AMD classification.
Alcohol consumption
Before the baseline center visits, participants received a checklist on which they 
indicated all foods and drinks they had consumed at least once during the preced-
ing year. The completed checklist formed the basis of an interview, using an exten-
sive semi quantitative food frequency questionnaire at the study center by a trained 
dietician.25 The dietary interviews were performed using a computer program that 
simultaneously checked the data. Participants reported the number of alcoholic 
beverages they consumed on a weekly basis in each of four categories: beer, wine, 
moderately strong alcoholic beverages such as port wine or sherry, and liquor. Non-
drinkers were considered abstainers. A “drink” was defined as 200 ml of beer that 
contained 8.0 g of ethanol, 100 ml of wine that contained 10.0 g of ethanol, 75 ml 
of moderately strong alcohol types that contained 10.5 g of ethanol, or 50 ml of 
liquor that contained 14.0 g of ethanol.26 By adding the amounts of ethanol in the 
four groups we calculated the total consumption of alcohol per participant in grams 
per day. Because most of the moderately strong alcohol drinks were wine types, this 
category was combined with the wine category in the analyses leading to three 
nonexclusive groups of persons drinking beer, wine and liquor. The alcohol con-
sumption was divided into no drinking, use of ≤ 10 g, > 10-≤ 20 g, and > 20 g/day.
Assessment of confounders
Information on all potential confounders was collected at baseline. During a home 
interview, trained research assistants asked participants for their smoking habits. 
Smoking was categorized as current, past or never smoker. Systolic and diastolic 
blood pressures were measured twice at the right brachial artery in a sitting position 
with a random zero sphygmomanometer. The average of these two measurements 
was used to determine blood pressure levels. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared (kg/m2). Non-fasting 
blood samples were obtained from all participants. Serum total cholesterol and 
high-density lipoprotein (HDL) levels were measured by an automated enzymatic 
procedure. Genotypes of complement factor H (CFH Y402H) polymorphism (1277 
T/C, rs1061170), were determined in 2-ng genomic DNA extracted according to 
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standard procedures from leukocytes with the Taqman allelic discrimination assay 
(Applied Biosystems, Foster City, California).
Data analysis
We estimated the risk of iAMD associated with alcohol consumption with Cox’s pro-
portional hazard regression analysis. Follow-up time in years was used as time-axis 
of the model. The associations are presented as hazard ratios (HRs) taking time to 
event into account, which can be interpreted as relative risks, with 95% confidence 
intervals (CIs). Non-drinkers were used as reference category. The Cox proportional 
hazard regression models were repeated for each category of alcoholic beverage. 
All analyses were initially corrected for age and sex. Analyses were repeated with 
possible confounders added to the model (smoking, systolic and diastolic blood 
pressure, total cholesterol and HDL cholesterol, body mass index, and the comple-
ment factor H Y402H SNP) using SPSS for Windows, version 11.0 (SPSS Inc., 2001, 
Chicago, IL).
results
At baseline, gradable fundus transparencies were available from 6418 participants, 
of whom 476 (7.4%) had early AMD and 106 (1.7%) late AMD. Of the 5836 persons at 
risk for any AMD, 4914 (77.9% of those at risk) participated in at least one follow-up 
examination. Persons did not participate in follow-up examinations due to refusal, 
death or loss to follow-up. Our study population consisted of 4229 (67.0%) partici-
pants from whom data on alcohol consumption were available. 
Baseline characteristics of these participants are shown in table 1. The average time 
between baseline and first follow-up examination was 2.0 years, between baseline 
and second follow-up 6.5 years, and between baseline and third follow-up 11.1 
years. During a mean follow-up time of 8.0 years (range 0.3 to 13.9 years), 600 cases 
of iAMD were identified, of whom 519 had early iAMD and 81 late iAMD. 
For each risk analysis for a subtype of AMD, the other AMD cases were removed 
from the study population as indicated below tables 2 and 3. Table 2 shows that 
after correction for age and sex, total alcohol consumption, analyzed in categories, 
was not associated with early or late iAMD. Because etiologic mechanisms could dif-
fer between dry and wet AMD, we analyzed these two end stages separately. Risk of 
dry iAMD seemed to increase with higher alcohol intake where as for wet iAMD the 
risk seemed to decrease with higher alcohol consumption (table 3). However, these 
associations were not statistically significant and 95% CIs were large. We further 
investigated the results for dry and wet AMD by calculating a trend using alcohol 
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table 1: Baseline characteristics and AMD status in 4229 participants
No AMD
n = 3629
Early AMD
n = 519
Late AMD
n = 81
Age, years 66.3 (7.2)* 68.0 (7.1) 71.3 (6.4)
Sex, female (%) 2166 (59.7) 295 (56.8) 49 (60.5)
Smoking status (%)
 Never 1218 (33.7) 172 (33.3) 22 (27.5)
 Former 1567 (43.4) 230 (44.5)  38 (47.5)
 Current 827 (22.9) 115 (22.2)  20 (25.0)
Diabetes Mellitus (%) 318 (8.8) 33 (6.4)  8 (7.4)
Body Mass Index, kg/m  
2 26.4 (3.6) 26.3 (3.5) 26.1 (3.1)
Systolic blood pressure, mm Hg 137.1 (21.5) 138.9 (20.3) 137.6 (19.9)
Diastolic blood pressure, mm Hg 73.9 (11.0) 73.5 (11.8) 70.8 (10.8)
Total cholesterol, mmol/L 6.7 (1.2) 6.6 (1.2) 6.7 (1.1)
HDL cholesterol, mmol/L 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
Complement factor H genotype (%)
 TT 1437 (43.8) 185 (39.7) 16 (20.5)
 CT 1469 (44.8) 211 (45.3) 36 (46.2)
 CC 372 (11.3) 70 (15.0) 26 (33.3)
Daily alcohol consumption
 Non-drinker 704 (19.4) 90 (17.3) 15 (18.5)
 ≤ 10 g 1638 (45.1) 235 (45.3) 37 (45.7)
 > 10 g - ≤ 20 g 568 (15.7) 82 (15.8) 11 (13.6)
 > 20 g 719 (19.8) 112 (21.6) 18 (22.2)
* Means and standard deviations between brackets, unless otherwise indicated 
table 2: Risk of early and late AMD according to level of alcohol consumption*
Daily alcohol consumption Total participants Cases Hazard ratio
95% CI**
Hazard ratio
95% CI***
Early AMD
Non-drinker 794 90 1.00 (reference) 1.00 (reference)
≤ 10 g 1873 235 1.01 (0.79-1.29) 1.00 (0.76-1.30)
> 10 g - ≤ 20 g 650 82 1.04 (0.76-1.40) 0.98 (0.70-1.36)
> 20 g 831 112 1.11 (0.83-1.48) 1.10 (0.80-1.51)
Late AMD
Non-drinker 719 15 1.00 (reference) 1.00 (reference)
≤ 10 g 1675 37 0.94 (0.51-1.72) 1.00 (0.53-1.89)
> 10 g - ≤ 20 g 579 11 0.94 (0.43-2.08) 0.77 (0.33-1.80)
> 20 g 737 18 1.26 (0.61-2.60) 1.01 (0.46-2.21)
* Early AMD: n = 4229 - 81 late AMD cases
 Late AMD: n = 4229 - 519 early AMD cases
** adjusted for age and sex
***  additionally adjusted for smoking, systolic and diastolic blood pressure, total cholesterol, HDL 
cholesterol, BMI and CFH genotype status
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intake as a continuous measure in these models. Only in the case of dry AMD the 
test for trend was significant (fully adjusted model, p-value 0.04). In addition we 
did not find any beverage-specific associations with early or late iAMD (table 4). 
table 3: Risk of dry or wet AMD according to level of alcohol consumption*
Daily alcohol consumption Total 
participants
Cases Hazard ratio
95% CI**
Hazard ratio
95% CI***
Dry AMD
Non-drinker 708 4 1.00 (reference) 1.00 (reference)
≤ 10 g 1648 10 0.93 (0.29 - 2.99) 1.10 (0.32 - 3.80)
> 10 g - ≤ 20 g 573 5 1.58 (0.42 - 6.04) 1.38 (0.31 - 6.16)
> 20 g 731 12 3.09 (0.93 - 10.27) 3.27 (0.88 - 12.19)
Wet AMD
Non-drinker 715 11 1.00 (reference) 1.00 (reference)
≤ 10 g 1665 27 0.95 (0.47 - 1.92) 0.96 (0.45 - 2.03)
> 10 g - ≤ 20 g 574 6 0.71 (0.26 - 1.96) 0.60 (0.21 - 1.72)
> 20 g 725 6 0.59 (0.21 - 1.68) 0.40 (0.13 - 1.25)
* Dry AMD: n = 4229 - 519 early AMD cases - 50 wet AMD cases
 Wet AMD: n = 4299 - 519 early AMD cases – 31 dry AMD cases
** adjusted for age and sex
***  additionally adjusted for smoking, systolic and diastolic blood pressure, total cholesterol, HDL 
cholesterol, BMI and CFH genotype status
table 4: Risk of early or late AMD by level of consumption of different types of alcoholic beverages 
adjusted for age and sex
Early AMD Late AMD
Total Cases Hazard ratio
95% CI
Total Cases Hazard ratio
95% CI
Daily beer consumption
Non-drinker 794 90 1.00 (reference) 719 15 1.00 (reference)
≤ 10 g 598 69 0.79 (0.53 - 1.15) 536 7 0.63 (0.20 - 1.98)
> 10 g - ≤ 20 g 95 8 0.66 (0.31 - 1.41) 88 1 0.82 (0.09 - 7.20)
> 20 g 74 12 1.28 (0.66 - 2.48) 64 2 1.94 (0.35 - 10.67)
Daily wine consumption
Non-drinker 794 90 1.00 (reference) 719 15 1.00 (reference)
≤ 10 g 1738 214 0.99 (0.78 - 1.27) 1562 38 1.04 (0.57 - 1.89)
> 10 g - ≤ 20 g 377 51 1.18 (0.83 - 1.67) 334 8 1.39 (0.58 - 3.32)
> 20 g 235 35 1.32 (0.89 - 1.96) 202 2 0.60 (0.13 - 2.63)
Daily liquor consumption
Non-drinker 794 90 1.00 (reference) 719 15 1.00 (reference)
≤ 10 g 740 94 0.90 (0.66 - 1.23) 655 9 0.45 (0.18 - 1.11)
> 10 g - ≤ 20 g 291 34 0.81 (0.54 - 1.23) 264 7 0.92 (0.35 - 2.44)
> 20 g 435 56 0.92 (0.64 - 1.33) 389 10 0.98 (0.40 - 2.40)
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We could not repeat the beverage-specific analyses after stratification by type of 
late AMD due to loss of power. Correction for additional covariates did not substan-
tially alter our results. 
discussion
In this cohort study we could not detect an association between overall alcohol 
consumption and early or late iAMD. In addition neither beer, wine nor liquor drink-
ers were at higher risk for AMD. With higher alcohol consumption, point estimates 
were increasing for dry iAMD and decreasing for wet iAMD. Although associations 
did not reach significance, the test for trend was significant for dry AMD. Whether 
there exists an association between alcohol consumption and dry AMD thus remains 
inconclusive. 
The Beaver Dam Study found cross-sectionally an association between beer con-
sumption in the past year and late AMD. In their 10-years incidence study current 
heavy alcohol consumption, defined as the consumption of four or more servings of 
alcoholic beverages daily, corresponding with 46 to 56 g of ethanol, was associated 
with wet late AMD (RR = 6.51, 95% CI: 1.41-30.2).11, 14 However, because only three 
current heavy drinkers developed late AMD, and confidence intervals about the risk 
ratios were large, these results should be interpreted with caution. In the Rotterdam 
Study only one current heavy drinker, classified in the same way as in the Beaver 
Dam Study, developed late wet AMD making comparable end stage-specific analy-
ses impossible due to lack of power. The Blue Mountains Eye Study, found cross-sec-
tionally no association with overall alcohol intake and more specifically with beer 
consumption. Consumption of spirits, however was associated with the presence of 
early AMD.16 They suggested that this is likely to be a chance finding because con-
sumption of spirits was not associated with the presence of any large drusen with 
a diameter greater than 125 μm or late AMD. The NHANES noted cross-sectionally 
a protective effect of moderate wine consumption on AMD.17 They did not correct 
for smoking and the at that time unknown complement factor H Y402H SNP, both 
strong risk factors for AMD, and recall bias might have resulted in their finding. This 
protective effect of wine consumption was also cross-sectionally described by the 
LALES study group, who found in addition a stronger association with AMD in heavy 
drinkers, and particularly in beer drinkers.12 This study concerns a Latino popula-
tion and biological mechanisms, e.g. the levels of alcohol dehydrogenase, could 
be different from those in a Caucasian population. The prospective Copenhagen 
Study found a non-significant trend of increased risk of any AMD with increasing 
daily alcohol intake be it with large CIs.15 One puzzling aspect in their results was 
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that they did not find an association between the established risk factor smoking 
and AMD. Another prospective study found no overall association between alcohol 
consumption and incidence of AMD, and only among women “excessive” alcohol 
consumption, defined as 30 g/day, was associated with early AMD and geographic 
atrophy (RR = 2.04, 95% CI: 1.22 - 3.42).13 In this study AMD was divided in two sepa-
rate groups, pooled early and dry AMD and wet AMD, because of possible different 
etiological mechanisms. Pooling of early and dry AMD is controversial, because both 
dry and wet AMD are likely to develop in persons with early AMD.27 A population-
based study, with an average follow-up time of 5 years,19 and the Physicians’ Health 
Study, with an average follow-up time of 12.5 years18, did not detect an association 
between alcohol intake and incident AMD. They could not perform beverage-spe-
cific analyses. 
In contrast with a case-control study, we assessed alcohol consumption before 
onset of AMD and recall bias is therefore not likely to be involved. In this study, self-
reported drinking habits may have introduced misclassification in exposure.28 In 
particular, this might have caused underreporting of alcohol consumption among 
heavy drinkers and have diminished our ability to detect an association. Yet, all oth-
er epidemiological studies investigating the possible association between alcohol 
consumption and AMD used self-reported data on alcohol intake. In addition, with 
increasing age, most drinkers reduce their alcohol consumption,29 thereby reducing 
power. The fact that we did not find an association could partly result from inclusion 
of former heavy drinkers in the group of no alcohol consumers and persons who 
did not drink because of their poor health status.30 However, additional exclusion 
of persons who had reduced their alcohol consumption in the last five years before 
baseline did not essentially change our results. The size of the Rotterdam Study, its 
population-based prospective design and the fact that we have taken a number of 
important confounders into account, strengthen our findings. Fundus images were 
graded in a standardized way by the same two well-trained graders at baseline and 
at all three follow-up visits. In addition alcohol consumption and type of beverages 
were classified based on a validated food frequency questionnaire. Therefore, we 
believe that our findings are an important addition to the existing studies on the 
subject.
In conclusion, neither overall nor specific alcohol consumption was associated with 
early or late iAMD in our population-based prospective cohort study. Considering 
the lack of consistent results among studies, we believe that alcohol consumption 
is not an important risk factor for AMD.
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ABstrAct
Purpose: It has been suggested that early menopause increases the risk of aging 
macula disorder (AMD), the major cause of incurable blindness with a dry and wet 
late subtype, and that exposure to endogenous or postmenopausal exogenous 
estrogens reduces this risk. This study was undertaken to investigate whether 
genetic variations in the estrogen receptor α (ESR1) gene were associated with inci-
dent AMD.
methods: In the Rotterdam Study, a prospective population-based cohort study 
of participants aged 55 years and older, associations between ESR1 PvuII-XbaI hap-
lotypes and incident early or late AMD were studied in 4571 participants after a 
mean follow-up time of 7.7 years. Cox proportional hazards regression was used to 
estimate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs), with 
adjustment for the most common confounders.
results: ESR1 PvuII-XbaI haplotype 1 was a risk factor for late AMD. Persons with two 
copies of haplotype 1 were at 3.20 (95% CI: 1.47-6.99) times higher risk for late AMD 
than non-carriers of haplotype 1, after adjustment for age and sex. This increase 
was more pronounced for wet AMD (HR = 4.29; 95% CI, 1.47-12.49) after adjustment 
for age, sex, smoking and complement factor H genotype. Correction for additional 
confounders, including age at menopause, use of hormone replacement therapy, 
blood pressure, and body mass index did not essentially alter the findings. 
conclusion: Persons with one or two copies of ESR1 PvuII-XbaI haplotype 1 have an 
increased risk of late AMD, especially of the wet form.
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introduction
Aging macula disorder (AMD), as we now prefer to call age-related macular degen-
eration,1 is a multifactorial disease that affects the center of the retina, the macula 
lutea, resulting in a central scotoma in the visual field.2-4 The pathogenesis of AMD 
is still not clear, and therapeutic strategies are limited. In our rapidly aging popula-
tion, with a predicted doubling by 2020 of the persons with blindness due to AMD, 
it is important to identify risk factors for AMD, to develop possible preventive and 
therapeutic strategies. 
Diminished exposure to endogenous estrogens as in early menopause has been 
cross-sectionally associated with AMD, and post-menopausal hormone replace-
ment therapy seems to protect against the disease.5-8 Although some studies could 
not corroborate these findings,9, 10 the role of estrogen deficiency in the pathogen-
esis of AMD should be further explored. 
Estrogens are steroid hormones that regulate growth, differentiation, and function 
of male and female reproductive tracts, mammary glands, and the skeletal and car-
diovascular systems.11 They mediate their effects through two distinct intracellular 
estrogen receptors (ERs): α (ESR1) and β (ESR2). After binding of estrogen to the 
ERs, they become transcription factors to modulate gene expression.12 The ESR1 
gene is located on chromosome 6q25. It consists of at least eight exons and spans 
more than 400 kb (http://www.ncbi.nlm.nih.gov/SNP provided in the public domain 
by National Center for Biotechnology Information, Bethesda, MD). Many common 
variations in DNA sequence (polymorphisms) of the ESR1 gene have been identi-
fied, including single nucleotide polymorphisms (SNPs). The two most studied SNPs 
are the adjacent PvuII (rs2234693), a T/C transition in intron 1, and XbaI (rs9340799), 
a G/A transition located 46 bp downstream of the PvuII polymorphism. The SNPs 
are localized in the first intron, 397 and 351 bp upstream of exon 2. It is not yet 
clear whether they have functional consequences. However, these SNPs, have been 
associated with several different phenotypes, such as osteoporosis, Alzheimer’s 
disease, and cardiovascular disease.13-16 Recently it has been demonstrated that, in 
postmenopausal women, ESR1 PvuII-XbaI haplotype 1 is associated with decreased 
serum estradiol levels in an allele-dose dependent manner.17 
The ESR1 protein is expressed in a variety of tissues, and the presence of ESR1 has 
also been demonstrated in the retina, suggesting that estrogens may have a role 
in retinal biology.18-20 We set out to study whether SNPs in the ESR1 gene are a risk 
factor for AMD. 
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methods
Population 
The Rotterdam Study is a prospective, population-based cohort study investigat-
ing the incidence and determinants of chronic disabling diseases in the elderly. All 
inhabitants aged 55 years or older living in one suburb of Rotterdam, the Nether-
lands were invited to participate in the study.21 Of the 10,275 eligible individuals, 
7983 (78%) participated. The ophthalmologic part of the study started after screen-
ing of the participants had begun, leading to 6780 ophthalmic participants-again, 
a 78% response rate. The study was conducted according to the tenets of the Dec-
laration of Helsinki, and the medical ethics committee of the Erasmus University 
approved the study protocol. A written informed consent was obtained from all 
persons. Baseline examinations, including a home interview and physical examina-
tion at the research center took place between March 1990 and July 1993. Three 
follow-up examinations took place from September 1993 to the end of 1994, from 
1997 to 1999, and from 2000 to the end of 2004. 
AMD definition
To diagnose AMD, 35° color transparencies were taken of the macular area of each 
eye (TRV-50VT fundus camera; Topcon Corp., Tokyo, Japan) after dilatation of the 
eyes with tropicamide 0.5% and phenylephrine 5%. These images (digitized from 
the last follow-up examination on) were graded with 12.5x magnification according 
to the International Classification and Grading System for age-related maculopathy 
(ARM) by the same two trained professionals grading AMD from baseline on, who 
were masked for all other determinants.21-24 We only changed the terminology from 
early and late ARM in early and late AMD and categorized the range of AMD fundus 
signs into five mutually exclusive stages 0 to 4 that had an increasing risk of late 
AMD.25 No AMD was defined as stage 0, no signs of AMD at all or only hard drusen 
(< 63 μm); stage 1 as soft distinct drusen (≥ 63 μm) or only pigmentary abnormalities. 
Because many participants with only one large druse or one hyperpigmentation in 
this system are classified as stage 1 and because we wanted to separate participants 
with marked AMD from those with only limited signs, in the present analyses, we 
considered stage 1 as no AMD. Thus, we classified as early AMD stage 2, soft, indis-
tinct drusen (≥ 125 μm) or reticular drusen only, or soft, distinct drusen (≥ 63 μm) 
with pigmentary abnormalities, and as stage 3, soft, indistinct drusen (≥ 125 μm) 
or reticular drusen with pigmentary abnormalities. Stage 4 was similar to late AMD, 
subdivided in dry (geographic atrophy) and wet (neovascular) AMD.25 The disease 
in each person was classified according to the highest stage of AMD in either eye. 
Early incident (i)AMD was defined as no AMD at baseline and early AMD in at least 
Estrogen receptor alpha gene polymorphisms associated with incident aging macula disorder 69
one eye at follow-up. Late iAMD was classified as either no or early AMD at baseline 
and presence of late AMD in either eye at follow-up. Lesions that were considered 
to be the result of generalized disease, such as diabetic retinopathy, chorioretinitis, 
high myopia, trauma, congenital diseases, or photocoagulation for reasons other 
than for wet AMD, were excluded from the AMD diagnosis.
Genotyping
DNA was extracted from peripheral leukocytes according to standard procedures. 
All participants were genotyped for the PvuII (rs2234693; c.454-397T>C) and the 
XbaI (rs9340799; c.454-351A>G) SNPs. Genotypes were also determined for the 
complement factor H Y402H polymorphism, which is a major risk factor for AMD 
(described later). Genotypes were determined in 5 ng genomic DNA with the allelic 
discrimination assay (Taqman; Applied Biosystems, Foster City, CA). Primer and 
probe sequences were optimized with the SNP assay-by-design service of Applied 
Biosystems. Reactions were performed on a sequence detection system (Taqman 
Prism 7900HT; ABI) 384-well format. We used the genotype data for each of the two 
ESR1 SNPs to infer the haplotypes for each individual using the haplotype recon-
struction program PHASE.26 The alleles were defined as haplotypes, such as T-A rep-
resenting a thymidine (T) nucleotide at the PvuII polymorphic site and an adenos-
ine (A) nucleotide at the XbaI polymorphic site. We studied haplotypes based on 
these adjacent polymorphisms, to enhance genetic resolution. Haplotype alleles, 
based on the combination of these two SNPs, were coded as haplotype numbers 1 
through 4 in order of decreasing frequency in the population (1, T-A; 2, C-G; 3, C-A; 
and 4, T-G).27, 28
Population for Analysis
At baseline, gradable fundus transparencies were available for 6418 participants, 
of whom 476 (7.4%) had early AMD and 106 (1.7%) late AMD. Of the 6312 persons 
at risk for any AMD, 4914 (77.9% of those at risk) participated in at least one fol-
low-up examination and in 4571 (72.4%) of them, haplotype data were available. 
Persons did not participate in follow-up examinations due to refusal, death, or loss 
to follow-up. Haplotype data were missing for persons who at baseline only had 
an interview and did not visit the research center, refused blood sampling, or from 
whom no blood was available due to various logistic reasons. For each risk analysis 
for a subtype of AMD, the other AMD cases were removed from the study popula-
tion as indicated in table footnotes.
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Assessment of Confounders
Information on all potential confounders was collected at baseline. During a home 
interview, participants were asked by trained research assistants about smoking 
habits, and women about age at menopause and use of hormone replacement ther-
apy. Smokers were categorized as current, past, or never. In the research center, sys-
tolic and diastolic blood pressures were measured twice at the right brachial artery 
with a random zero sphygmomanometer with the participant in a sitting position. 
The average of these two measurements was used to determine blood pressure 
levels. Body mass index was calculated as weight in kilograms divided by height 
in meters squared. Genotypes of complement factor H (CFH Y402H) polymorphism 
(1277 T/C, rs1061170), were determined in 2-ng genomic DNA extracted according 
to standard procedures from leukocytes with the allelic discrimination assay (Taq-
man; ABI). Confounder data for smoking, body mass index, and systolic and diastolic 
blood pressure were missing in 1% of the participants, and data for CFH genotype 
in 10%. In women, confounder data on hormone replacement therapy and age at 
menopause were missing in 4% of the participants. 
Data analysis
One-way analysis of variance (ANOVA), for continuous variables, and Pearson’s 
chi-square for dichotomous variables were used to compare possible confounders 
between participants grouped by the haplotype of interest. The observed geno-
type distributions were compared using Pearson’s chi-square test to determine 
whether they were in Hardy Weinberg equilibrium. The associations between 
ESR1 haplotype stratified on allele copy number (0, 1 or 2) and early or late iAMD, 
stratified on type of end stage were investigated with the Cox proportional hazards 
model to compute hazard ratios (HRs) and corresponding 95% confidence intervals 
(CIs). To calculate a trend, ESR1 haplotype 1 was used as a continuous measure in 
the model. As a reference group, we used persons with only stage 0 or 1 AMD at 
baseline and at follow-up. Follow-up time in years was used as time axis of the 
model. HRs can be interpreted as relative risks. All analyses were adjusted for age 
and sex. To account for potential confounding, additional adjustments were made 
for smoking, and the complement factor H Y402H SNP, major risk factors associated 
with AMD.29-32 Further adjustment for blood pressure and body mass index did not 
essentially alter our results (data not shown). Based on previous analyses we chose 
haplotype 1 as the risk allele.15, 28, 33, 34 To evaluate the effect of sex we performed 
sex-specific analyses for early and late iAMD. In women, analyses were additionally 
adjusted for the potential confounding effects of age at menopause and any use of 
HRT. All analyses were performed with commercial software (SPSS, ver. 11.0; SPSS 
Inc., Chicago, IL).
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results
Baseline characteristics of the 4571 participants are shown in Table 1. ESR1 haplo-
type 1 was not associated with any of the baseline characteristics, including age at 
menopause and use at any time of hormone replacement therapy. After an average 
table 1: Baseline characteristics of 4571 participants, stratified on number of allele copies of ESR1 
haplotype 1 (T-A).
Number of allele copies ESR1 haplotype 1 0 1 2 p-value
Number of participants (%) 1008 (22.1) 2285 (50.0) 1278 (28.0)
Age (y) 67.1 (7.6) 67.1 (7.6) 66.9 (7.7) 0.7
Sex, female (%) 581 (57.6) 1322 (57.9) 739 (57.8) 0.9
Smoking status (%)
 Never 346 (34.5) 760 (33.6) 416 (32.9)
 Current 229 (22.8) 496 (21.9) 305 (24.1) 0.5
 Past 428 (42.7) 1008 (44.5) 545 (43.0) 0.7
Systolic blood pressure, (mm HG) 137.0 (21.2) 137.7 (21.4) 137.9 (21.8) 0.6
Diastolic blood pressure, (mm HG) 73.7 (11.0) 73.7 (11.0) 74.1 (11.2) 0.5
Body Mass Index (kg/m 2) 26.3 (3.6) 26.3 (3.6) 26.4 (3.7) 0.9
Complement Factor H Y402H SNP (%)
 Noncarrier 422 (43.6) 939 (42.9) 520 (42.4)
 Heterozygous 429 (44.4) 977 (44.6) 556 (45.3) 0.9
 Homozygous 116 (12.0) 274 (12.5) 151 (12.3) 0.9
Age at menopause (y) 48.7 (4.9) 48.8 (5.1) 49.1 (4.8) 0.3
Ever use of HRT (%) 84 (15.1) 199 (15.7) 101 14.2) 0.7
Data are the means with standard deviations in parentheses, unless otherwise indicated.
table 2: Risk of early or late iAMD according to ESR1 haplotype 1 (T-A).
Number of copies 
of ESR1 haplotype 1
Total 
participants
Cases (%) Risk adjusted for age 
and sex
Risk adjusted for age, sex, 
smoking and CFH genotype
Early AMD
0 1000 116 (11.6%) 1.00 (reference) 1.00 (reference)
1 2228 265 (11.9%) 1.07 (0.86 - 1.33) 1.04 (0.83 - 1.30)
2 1248 163 (13.1%) 1.18 (0.93 - 1.50) 1.16 (0.91 - 1.48)
p-trend 0.16 0.21
Late AMD
0 892 8 (0.9%) 1.00 (reference) 1.00 (reference)
1 2020 57 (2.8%) 3.39 (1.62 - 7.11) 3.07 (1.46 - 6.46)
2 1115 30 (2.7%) 3.20 (1.47 - 6.99) 2.85 (1.30 - 6.25)
p-trend 0.01 0.02
Early AMD: n = 4571 - 95 late AMD cases
Late AMD: n = 4571 - 544 early AMD cases
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table 3: Risk of dry or wet late iAMD according to ESR1 haplotype 1 (T-A).
Number of copies of 
ESR1 haplotype 1
Total 
participants
Cases (%) Risk adjusted for age 
and sex
Risk adjusted for age, sex, 
smoking and CFH genotype
Dry AMD
0 888 4 (0.5%) 1.00 (reference) 1.00 (reference)
1 1989 26 (1.3%) 3.13 (1.09 - 8.98) 2.76 (0.95 - 8.01)
2 1093 8 (0.7%) 1.72 (0.52 - 5.71) 1.41 (0.41 - 4.85)
p-trend 0.57 0.79
Wet AMD
0 888 4 (0.5%) 1.00 (reference) 1.00 (reference)
1 1994 31 (1.6%) 3.72 (1.31 - 10.55) 3.50 (1.23 - 9.94)
2 1107 22 (2.0%) 4.71 (1.62 - 13.66) 4.29 (1.47 - 12.49)
p-trend 0.001 0.01
Dry AMD: n = 4571 - 544 early AMD cases - 57 wet AMD cases
Wet AMD: n = 4571 - 544 early AMD cases - 38 dry AMD cases
table 4: Risk of early or late iAMD according to ESR1 haplotype 1 (T-A) stratified on sex.
Number of copies of 
ESR1 haplotype 1
Total 
participants
Cases (%) Risk adjusted for age Risk adjusted for age, 
smoking and CFH 
genotype* 
Men
Early AMD
0 423 53 (12.5%) 1.00 (reference) 1.00 (reference)
1 935 114 (12.2%) 1.01 (0.73 - 1.40) 1.02 (0.73 - 1.42)
2 530 74 (14.0%) 1.14 (0.80 - 1.63) 1.15 (0.80 - 1.66)
p-trend 0.43 0.42
Late AMD
0 374 4 (1.1%) 1.00 (reference) 1.00 (reference)
1 849 28 (3.3%) 3.22 (1.13 - 9.19) 3.02 (1.05 - 8.72)
2 465 9 (1.9%) 1.88 (0.58 - 6.09) 1.71 (0.51 - 5.71)
p-trend 0.49 0.58
Women
Early AMD
0 577 63 (10.9%) 1.00 (reference) 1.00 (reference)
1 1293 151 (11.7%) 1.12 (0.83 - 1.50) 1.10 (0.81 - 1.49)
2 718 89 (12.4%) 1.21 (0.88 - 1.68) 1.13 (0.81 - 1.61)
p-trend 0.24 0.48
Late AMD
0 518 4 (0.8%) 1.00 (reference) 1.00 (reference)
1 1171 29 (2.5%) 3.51 (1.23 - 9.99) 3.10 (1.07 - 8.90)
2 650 21 (3.2%) 4.55 (1.56 - 13.26) 3.52 (1.18 - 10.46)
p-trend 0.01 0.03
* Plus age at menopause and use (ever) of HRT in women.
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follow-up time of 7.7 years (range 0.3-13.9 years), 639 (14.0%) persons had iAMD, of 
whom 544 (11.9%) had early iAMD, and 95 (2.1%) had late iAMD, of whom 38 had 
dry and 57 wet iAMD. For early iAMD cases the average follow-up time from base-
line to the development of AMD was 4.5 years and for late iAMD cases 6.2 years. We 
observed the four possible PvuII-XbaI haplotype alleles in the following frequencies: 
haplotype 1 (T-A) 53.0%, haplotype 2 (C-G) 35.0%, haplotype 3 (C-A) 12.0% whereas 
haplotype 4 (T-G) was not present in our study population. Genotype and allele 
distributions were in Hardy-Weinberg Equilibrium.
ESR1 haplotype 1 was associated with late iAMD (Table 2). Persons with one copy of 
haplotype 1 were at 3.39 (95% CI, 1.62-7.11) times higher risk and for persons with 
two copies, this was 3.20 (95% CI, 1.47-6.99). After stratification by type of end stage 
(Table 3), it seemed that particularly wet iAMD was responsible for this association. 
Individuals with one copy had a 3.72 (95% CI, 1.31-10.55) times higher risk of wet 
iAMD, whereas this was 4.71 (95% CI, 1.62-13.66) for individuals with two copies. HRs 
were also increased for dry iAMD, but they did not reach significance. Early iAMD 
was not associated with ESR1 haplotype 1. Additional correction for smoking and 
complement factor H also did not essentially alter our results. After stratification on 
sex (Table 4), HRs were increased in the men with one or two copies of haplotype 1, 
but this only reached statistical significance in the men with one copy and the risk of 
late iAMD. In the women we found an association with late iAMD: women with one 
copy of haplotype 1 had a 3.10 (95% CI, 1.07 - 8.90) times higher risk and this was for 
the women with two copies 3.52 (95% CI, 1.18 - 10.46). Further stratification on type 
of end stage was not possible due to lack of power. Multivariate adjustment, includ-
ing age at menopause and any use of HRT, did not substantially change these HRs. 
Additional stratified analysis by genotypes of the CFH Y402H polymorphism to test 
for gene-gene interaction and by smoking status to test for gene-environmental 
interaction did not show any significant associations (data not shown).
discussion
In this large, prospective population-based study, we demonstrated that the ESR1 
PvuII-XbaI haplotype 1 was strongly associated with late iAMD. After stratification 
by type of end stage, wet iAMD showed highly significant HRs. Although point esti-
mates were elevated in dry iAMD, there was no significant effect visible, probably 
due to lack of power. Therefore, it remains inconclusive whether an association with 
ESR1 PvuII-XbaI haplotype 1 exists. 
The Rotterdam Study is a large study with a population-based prospective design, 
which increases the reliability of the associations found. Fundus images were grad-
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ed in a standardized way by the same two well-trained graders at baseline and at all 
three follow-up visits. Differential misclassification is unlikely, because AMD graders 
were masked for the presence of ESR1 PvuII-XbaI haplotype 1 status and haplotype 
data were collected without knowledge of AMD status. There was loss to follow-
up due to the older age of the participants, and thus only the healthier persons 
were able to participate in the follow-up visits. This leads to an underestimation 
of the strength of the associations. If especially persons with one or two copies of 
ESR1 haplotype 1 with iAMD had not participated, selection bias would have been 
introduced. We think this is unlikely because people were unaware of their ESR1 
haplotype 1 status, and only in case of late iAMD would they be aware of symptoms. 
Genetic association studies can be influenced by population heterogeneity. In our 
study, 99% of the participants were Dutch whites and represent an ethnically homo-
geneous and representative sample of the population from The Netherlands. 
We could not replicate the association between ESR1 PvuII-XbaI haplotype 1 and 
late AMD in our prevalent data. The possibility exists that our associations are a 
chance finding. However, the Rotterdam Study is a large study with a population-
based prospective design, which increases the reliability of the associations found. 
We hypothesized that selective mortality may be involved. Persons with one or two 
copies of ESR1 haplotype 1 have a higher risk of AMD, and if these persons also die 
earlier, it could explain the discrepancy between prevalent and iAMD. An indepen-
dent incidence study is needed to confirm our findings.
How could these ESR1 SNPs influence the risk of iAMD? A hypothesis regarding 
functionality of these polymorphisms is that expression of ESR1 is changed through 
altered binding of transcription factors, perhaps as a direct result of the PvuII and/or 
XbaI polymorphisms or through linkage disequilibrium with one or more functional 
sequence variations elsewhere in the ESR1 gene within the linkage disequilibrium 
block. In support of this hypothesis, it was recently demonstrated that the PvuII C-
allele produces a functional binding site for the transcription factor B-myb and the 
PvuII T-allele eliminates this site, suggesting a potential functional polymorphism.35 
The presence of this allele may result in a substantially lower ESR1 transcription or 
production of isoforms with different features; therefore, if a decreased amount of 
ESR1 is present or ESR1 with an altered sensitivity for estrogen, estrogen signal-
ing may be less effective. This resembles a situation in which estrogen activity is 
decreased.15, 35 Carriers of the T-allele would be at higher risk for diseases associated 
with low estrogen levels, such as AMD. 
Recently an association was found between ESR1 PvuII-XbaI haplotype 1 and 
decreased estradiol levels in a small randomly selected subset of postmenopausal 
women (n = 631) in the Rotterdam Study.17 We could not analyze the association 
between iAMD and estradiol levels due to low power. It was hypothesized that the 
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lower ESR1 expression caused by the PvuII T-allele leads to a lower expression of 
an enzyme in the estrogen synthesis pathway and thus reduces estrogen levels.17 
In all men estrogen serum levels are substantially higher than in postmenopausal 
women and this could partially mask the genotypic reduction. This fits with the fact 
that ESR1 PvuII-XbaI haplotype 1 was the most strongly related with iAMD in the 
women. Lower serum levels of estrogen in men and especially in postmenopausal 
women, particularly if they have one or two copies of this haplotype, could lead to 
reduced transcription of the ESR1.18 Whether these ESR1 variants have functional 
consequences must be investigated, as we lack definite evidence at this moment. In 
addition, we could not detect an association between HRT and iAMD, probably due 
to the low number of women taking HRT (n = 69) at baseline.36
Several studies have demonstrated the presence of ERs in human, bovine, and rat 
retinas, principally in the retinal pigment epithelium and choroid.18-20 Retinal pig-
ment epithelium ERs are functional, and transcriptional active and estrogen-medi-
ated regulation of genes is important in regulating the turnover of extracellular 
matrix and in maintaining its basement (Bruch’s) membrane.19 Dysregulation in the 
production of matrix metalloproteinase-2, a gelatinase regulated by estrogens that 
degrades extracellular matrix components, is thought to contribute to the forma-
tion of deposits around Bruch’s membrane.12, 37 Because ESR1 haplotype 1 was not 
associated with early iAMD, we assume that this haplotype influences more the pro-
gression of early AMD toward wet AMD instead of the initiation of drusen. Deposits 
around Bruch’s membrane may promote a proangiogenic response, by binding to 
integrins or by modifying integrin expression on endothelial cells. This response 
stimulates the growth of choroidal neovascularisation,38 the basic mechanism of 
wet AMD. 
In conclusion, we showed an increased risk of wet iAMD in persons with one or two 
copies of ESR1 PvuII-XbaI haplotype 1. This association was not explained by addi-
tional risk factors, marking ESR1 PvuII-XbaI haplotype 1 as a possible independent 
risk factor for wet iAMD. This study supports a pathophysiological role of estrogen 
in the development of AMD.
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Background/aims: Pro-angiogenic factors are believed to play a role in the patho-
genesis of choroidal neovascularization. Insulin-like growth factor (IGF-1) is a known 
pro-angiogenic factor that participates in ocular neovascularization. The purpose of 
our study was to examine if there exists an association between a micro satellite 
repeat polymorphism in the promoter region of the IGF-1 gene, which is associated 
with serum IGF-1 levels, and incident aging macula disorder (iAMD).
methods: In the Rotterdam Study, a prospective population-based cohort study of 
participants aged 55 years and older, associations between this polymorphism in 
the IGF-1 gene and early or late incident AMD (iAMD) were studied in 4821 partici-
pants. After a mean follow-up time of 7.7 years, 591 cases of early and 99 cases of 
late iAMD were identified. We used Cox proportional hazards regression to estimate 
hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). 
results: We did not find an association between this polymorphism in the IGF-1 
gene and risk of early (HR 1.11; 95% CI 0.84-1.47) or late (HR 0.97; 95% CI 0.50-1.90) 
iAMD. In particular no association was found with wet iAMD (HR 0.96; 95% CI 0.42-
2.24).
conclusion: Our findings do not support involvement of genetic variation in the 
IGF-1 gene in the development of AMD, and especially not of wet AMD.
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introduction
Age-related macular degeneration is one of the over 20, often descriptive, names for 
an affliction known for over 130 years,1 according to the pathophysiological thinking 
at a certain period. We prefer to name this now aging macula disorder, also abbrevi-
ated as AMD.2 At present treatment options are limited and are restricted to patients 
with wet AMD, the neovascular form of late AMD.3 Vascular growth factors are major 
effectors in this process. It is assumed that angiogenic growth factors produced by 
the RPE, such as insulin-like growth factor (IGF-1) and vascular endothelial growth 
factor (VEGF) play a role in the development of choroidal neovascularisation.4-6 
IGF-1 stimulates VEGF expression in RPE cells.7 Synthesis of IGF-1 and its receptor, 
and IGF-1 receptor protein were found in ocular neovascular membranes of patients 
with AMD.6 This makes the IGF-1 gene a candidate gene for especially wet AMD. 
IGF-I is a ubiquitous polypeptide that regulates growth, differentiation and prolifer-
ation of many types of cells, including human RPE cells. It is the product of the IGF-1 
gene, which has been mapped to chromosome 12.8 A polymorphism in the IGF-1 
gene 5’promoter region of the IGF-1 gene is associated with circulating serum IGF-1 
levels.9 This polymorphism contains a variable length of a cytosine-adenosine (CA)-
repeat sequence. Homozygous carriers of the most common 192 bp allele had the 
highest serum levels, while its absence was significantly associated with 20% lower 
circulating IGF-1 levels.9 Serum levels of IGF-1 are influenced by various factors such 
as age, growth hormone, insulin, diet and physical activity.10 This implies that this 
polymorphism in the IGF-1 gene could reflect chronic exposure to IGF-1 throughout 
the body more accurately than an incidental measurement of IGF-1 levels. 
We set out to test our hypothesis that persons homozygous for the 192 bp allele 
would be at higher risk for AMD and especially for wet AMD.
methods
Population
The Rotterdam Study is a prospective, population-based cohort study of cardiovas-
cular-, locomotor-, neurologic- and ophthalmologic diseases in the elderly.11 
In summary, all inhabitants aged 55 years or older living in a suburb of Rotterdam, 
the Netherlands were invited to participate in the study. Of the 10,275 eligible indi-
viduals, 7983 participated (78%). The ophthalmologic part of the study started after 
screening of the participants had begun, leading to 6780 ophthalmic participants, 
also with 78% response rate. The Rotterdam Study was approved by the medical eth-
ics committee of the Erasmus University and written informed consent was obtained 
82
Ch
ap
te
r 3
.2
from all participants. Baseline examinations, including a standardized home inter-
view and physical examination at the research center took place between March 
1990 and July 1993. Three follow-up examinations took place from September 1993 
to the end of 1994, from 1997 to 1999 and from 2000 to the end of 2004. 
AMD definition
To diagnose AMD, 35° color photographs were taken of the macular area of each 
eye (TRV-50VT fundus camera, Topcon Corporation, Tokyo, Japan) after dilatation of 
the pupils with tropicamide 0.5% and phenylephrine 5%. The fundus images and the 
digitized images from the last follow-up examination12 were graded with 12.5x mag-
nification according to the International Classification and Grading System for AMD.13 
In this system, all AMD fundus signs within a standard circle (diameter 6 mm) around 
the fovea are recorded. We deviated from this system by changing the name age-
related maculopathy in AMD. Two well-trained graders, each having 11 years of expe-
rience, graded the fundus images masked for most determinants of the participants. 
The grading procedures and graders were identical at baseline and at follow-up.12
We next categorized eyes into five mutually exclusive stages 0 to 4 according to fun-
dus signs that had an increasing risk of late AMD. No AMD was defined as stage 0, 
no signs of AMD at all or only hard drusen (< 63 μm), and stage 1 soft distinct drusen 
(≥ 63 μm), or only pigmentary abnormalities. Because many participants with only 
one large druse or one hyperpigmentation in this system are classified as stage 1 and 
because we wanted to separate participants with marked AMD from those with only 
limited signs, in the present analyses, we considered stage 1 as no AMD. Thus, we 
classified as early AMD stage 2, soft indistinct drusen (≥ 125 μm) or reticular drusen 
only, or soft distinct drusen (≥ 63 μm) with pigmentary abnormalities, and stage 3, 
soft indistinct drusen (≥ 125 μm) or reticular drusen with pigmentary abnormalities. 
Stage 4 was similar to late AMD with a dry and a wet form. Dry AMD was defined as 
any sharply demarcated round or oval area of apparent absence of the RPE, larger 
than 175 µm, with visible choroidal vessels, and no wet AMD. Wet AMD was defined 
as the presence of a serous or hemorrhagic detachment of the RPE and/or a sub 
retinal neovascular membrane and/or sub retinal hemorrhage, and/or periretinal 
fibrous scarring, even with patches of dry AMD. A person was classified according 
to the highest stage of AMD in either eye and in case both dry and wet AMD were 
present, as wet AMD. Early incident (i)AMD was defined as no AMD at baseline and 
early AMD in at least one eye at follow-up. Late iAMD was classified as either no or 
early AMD at baseline and presence of late AMD in either eye at follow-up. Lesions 
that were considered to be the result of other disease, such as diabetic retinopathy, 
chorioretinitis, high myopia, trauma, angioid streaks, or photocoagulation for rea-
sons other than for wet AMD, were excluded from AMD diagnosis.
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Measurements
Information on all potential confounders was collected at baseline. During a home 
interview, participants were asked for their smoking habits by trained research 
assistants. Smoking was categorized as current, past or never smoker. Systolic and 
diastolic blood pressures from the right upper arm were measured twice with a 
random zero sphygmomanometer with the participant in a sitting position. The 
average of these two measurements was used to determine blood pressure levels. 
Body mass index was calculated as weight in kilograms divided by height in meters 
squared (kg/m ²). Diabetes mellitus was considered to be present when persons cur-
rently used oral blood-glucose-lowering medication or insulin, or had a non-fasting 
or post-load glucose level above 11.0 mmol/L. 
Genotype determinations
Polymerase chain reaction (PCR) using genomic DNA from peripheral white blood 
cells was performed using oligonucleotide primers designed to amplify the poly-
morphic (CA)n repeat 1 kb upstream from the transcription site of the IGF-1 gene.
9 
Earlier, we identified 10 different alleles in the promoter region of the IGF-1 gene 
in a sample of 900 persons of the Rotterdam Study.9 Of these 88.4% were homozy-
gous or heterozygous for a 192-bp allele, suggesting that this is the common allele 
from which all other alleles originated. Consequently, the frequency of the other 
nine alleles was low. Based on this observation, using the common allele, our study 
population was divided into three possible genotypes: carriers homozygous for the 
192 bp allele (reference group), carriers heterozygous for the 192 bp allele and non-
carriers of the 192 bp allele. 
Genotypes of complement factor H (CFH Y402H) SNP (1277 T/C, rs1061170), were 
determined in 2-ng genomic DNA extracted according to standard procedures from 
leukocytes with the Taqman allelic discrimination assay (Applied Biosystems, Foster 
City, California). 
Population for analysis
At baseline, gradable fundus transparencies were available on 6418 participants, of 
whom 476 (7.4%) had early AMD and 106 (1.7%) late AMD. Of the 6312 persons at 
risk for any AMD, 4914 (77.9% of those at risk) participated in at least one follow-up 
examination. Persons did not participate in follow-up examinations due to refusal, 
death or loss to follow-up. Our study population consisted of 4821 (76.4% of those 
at risk) participants on whom blood specimens were available for IGF-1 genotyping. 
Genotype data were missing for persons who at baseline only had an interview and 
did not visit the research center, refused blood sampling, or of whom no blood was 
available due to random logistic reasons. 
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Data analysis
The observed genotype distributions were compared using a Pearson’s chi-square 
test to determine if they were in Hardy Weinberg equilibrium. General character-
istics of the total study population, stratified by genotype, were compared using 
one-way analysis of variance (ANOVA) for continuous variables, and Pearson’s chi-
square for dichotomous ones. We used Cox proportional hazards regression analysis 
to estimate relative risks and 95% confidence intervals (95% CIs). Follow-up time in 
years was used as time axis of the model. Hazard ratios can be interpreted as rela-
tive risks. Analyses were initially adjusted for age and sex. To account for potential 
confounding additional adjustments were made for smoking and the complement 
factor H Y402H SNP, major risk factors associated with AMD.14-17 All analyses were 
carried out using SPSS 11.0 (SPSS Inc., Chicago, USA).
results
During a mean follow-up time of 7.7 years (range 0.3 to 13.9 years), 690 cases of 
iAMD were identified, of which 591 (7.4%) had early iAMD and 99 (1.7%) late iAMD. 
Table 1 presents the baseline characteristics of the 4821 participants for each 
genotype group. Based upon the genotype classification, 2127 (44.1%) participants 
were homozygous, 2117 (43.9%) were heterozygous for the 192-bp allele and 577 
table 1: Baseline characteristics of 4821 participants at risk for AMD, stratified by IGF-1 genotype
Homozygous 
carriers 192-bp 
allele
Heterozygous 
carriers 192-bp 
allele
Non-carriers 192-
bp allele
p-value
Numbers (%) 2127 (44.1) 2117 (43.9) 577 (12.0)
Age, years 67.1 (7.7)* 66.9 (7.6) 67.3 (8.0) 0.4
Sex, female (%) 1238 (58.2) 1237 (58.4) 343 (59.4) 0.9
Smoking status (%)
 Current 489 (39.9) 489 (41.8) 108 (35.6) 0.1
 Past 882 (54.5) 925 (57.6) 270 (58.1) 0.1
Diabetes mellitus (%) 189 (9.1) 189 (9.2) 49 (8.6) 0.9
Systolic blood pressure, mm Hg 137.8 (21.6) 137.6 (21.4) 137.2 (21.7) 0.8
Diastolic blood pressure, mm Hg 73.8 (11.0) 74.1 (11.3) 73.1 (10.9) 0.2
Body Mass Index, kg/m2 26.4 (3.7) 26.3 (3.6) 26.3 (3.6) 0.5
CFH Y402H SNP (%)
 Heterozygous 868 (50.9) 862 (51.6) 225 (50.1) 0.8
 Homozygous 234 (21.9) 241 (22.9) 64 (22.2) 0.9
* Means with standard deviations in parentheses, unless otherwise indicated.
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(12.0%) were classified as non-carriers. Genotype distributions were in Hardy-Wein-
berg Equilibrium. Table 2 shows that the presence of the 192-bp allele was not sig-
nificantly associated with early or late iAMD. Because we particularly expected an 
association between wet iAMD and presence of the 192-bp allele, we stratified late 
iAMD in the dry and wet forms. Table 3 demonstrates that the presence of the 192-
bp allele was associated with neither of them.
discussion
We found that a polymorphism in the IGF-1 gene was no risk factor for early or late 
iAMD. Also no indication could be found that participants who were homozygous 
table 2: Associations between IGF-1 genotypes and incident early or late AMD
192-bp allele Total participants Cases (%) Model 1*
Hazard ratio
(95%CI)
Model 2**
Hazard ratio
(95%CI)
Early AMD
Homozygous carriers 2086 243 (11.6) 1.00 (reference) 1.00 (reference)
Heterozygous carriers 2073 266 (12.8) 1.14 (0.95 - 1.35) 1.12 (0.93 - 1.35)
Non-carriers 565 74 (13.1) 1.15 (0.89 - 1.49) 1.11 (0.84 - 1.47)
Late AMD
Homozygous carriers 1884 41 (2.2) 1.00 (reference) 1.00 (reference)
Heterozygous carriers 1851 44 (2.4) 1.16 (0.76 - 1.77) 0.96 (0.61 - 1.50)
Non-carriers 503 12 (2.4) 1.09 (0.57 - 2.07) 0.97 (0.50 - 1.90)
* Adjusted for age and sex
** Additionally corrected for smoking and CFH Y402H SNP carrier status
table 3: Associations between IGF-1 genotypes and incident dry or wet late AMD
192-bp allele Total participants Cases (%) Model 1*
Hazard ratio
(95%CI)
Model 2**
Hazard ratio
(95%CI)
Dry AMD
Homozygous carriers 1858 15 (0.8) 1.00 (reference) 1.00 (reference)
Heterozygous carriers 1826 19 (1.0) 1.37 (0.70 - 2.70) 0.94 (0.45 - 1.95)
Non-carriers 495 4 (0.8) 0.96 (0.32-2.90) 0.91 (0.30 - 2.76)
Wet AMD
Homozygous carriers 1869 26 (1.4) 1.00 (reference) 1.00 (reference)
Heterozygous carriers 1832 25 (1.4) 1.03 (0.60 - 1.79) 0.95 (0.54 - 1.67)
Non-carriers 499 8 (1.6) 1.14 (0.52 - 2.52) 0.96 (0.42 - 2.24)
* Adjusted for age and sex
** Additionally corrected for smoking and CFH Y402H SNP carrier status
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for this allele, with presumably the highest serum levels of IGF-1 were at risk for wet 
iAMD. 
Strengths of our study are its prospective population-based design, the large study 
sample, which increases the reliability of our findings, the standardized way in which 
fundus pictures were graded for diagnosing AMD, and the masking of the examiners 
for the determinants and confounders collected at baseline. Limitations are loss to 
follow-up, due to the fact that older and diseased persons were less likely to partici-
pate, resulting in a healthier study population. This may lead to an underestimation 
of the strength of the associations. Genetic association studies can be influenced by 
population heterogeneity. In our study, approximately 99% of the participants were 
white persons from the Netherlands and therefore represent an ethnically homoge-
neous and representative sample of the Dutch population. Potential confounding 
factors were dealt with in the analyses, but they did not substantially change the 
point estimates.
We can only speculate why we did not find an association between this polymor-
phism and iAMD. It is possible that there exists no association or that we can’t find 
it because of loss of power and a small effect. AMD probably is a complex disease, 
controlled by several genes with minor effects interacting with environmental 
factors, thereby influencing disease expression.18-20 Consequently the effect of a 
genetic polymorphism may be small and may not reach significance in a genetic 
association study.21 Compared with early AMD, fewer persons developed late AMD 
during follow-up, so loss of power could affect our analyses, particularly our end-
stage-specific analyses. If IGF-1 would influence only wet AMD and the effect of this 
polymorphism is small, an association might not be detected. 
The pathogenesis of retinal neovascularization is better understood than the patho-
genesis of choroidal neovascularization. Retinal hypoxia, due to occlusion of retinal 
vessels, is the driving force for retinal neovascularisation.22 IGF-1 influences angio-
genesis directly23 or through VEGF, which is an acknowledged stimulatory factor for 
retinal neovascularisation.7 VEGF is also involved in the development of choroidal 
neovascularisation.24 IGF-1 as well as hypoxia are thought to stimulate expression of 
VEGF in RPE cells.25, 26 RPE cells express high levels of VEGF and a potent antiangio-
genic factor, the pigment epithelium-derived factor (PEDF). It is hypothesized that a 
critical balance between these two factors is important to prevent the development 
of choroidal neovascularisation.27 Immunoreactivity of PEDF is lower in choroids of 
AMD patients compared with that in control persons, and VEGF immunoreactivity 
is similar in AMD patients and controls.28 The vitreous of patients with choroidal 
neovascularization due to AMD contains lower levels of PEDF compared to that of 
age-matched controls; this was not found for VEGF.29 It might be possible that a 
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decline in PEDF levels is more important in the pathogenesis of wet AMD, than an 
increase in VEGF levels. 
In this population-based cohort of elderly aged 55 years and older a polymorphism 
in the IGF-1 gene, was not a risk factor for iAMD and particularly not for wet AMD. 
These results do not support our hypothesis that this polymorphism contributes to 
the genetic susceptibility to AMD.
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ABstrAct
Purpose: Vascular endothelial growth factor (VEGF) is an important regulator 
of angiogenesis and a target for inhibition therapy in wet aging macula disorder 
(AMD). The purpose of our study was to examine whether genetic variation in the 
VEGF gene is associated with AMD and, especially, with its wet end stage. 
methods: In this prospective population-based cohort study among men and 
women aged 55 years and over, AMD was classified according to the modified Inter-
national Classification System on fundus color images. We determined genotypes 
and haplotypes for three functional VEGF single nucleotide polymorphisms (SNPs): 
C-2578A, G-1154A, and G-634C. Cox proportional hazards regression analyses were 
used to investigate possible associations between the individual SNPs and incident 
AMD (iAMD). We used the program Haplo.Stats to test the associations between 
VEGF gene haplotypes and iAMD.
results: Of 4228 participants at risk for early or late iAMD, for whom blood speci-
mens were available for VEGF genotyping, 514 developed early iAMD and 89 late 
iAMD (35 dry and 54 wet) after a mean follow-up of 7.4 years. None of the SNPs 
showed a significant association with early or late iAMD, especially not with wet 
iAMD. Haplotype analyses also detected no associations.
conclusion: Our a priori hypothesis that three common SNPs in the VEGF gene 
would be a risk factor for AMD, especially the wet form, could not be confirmed.
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introduction
Early fundus signs of aging macula disorder (AMD), as we now prefer to call age-
related macular degeneration,1 are yellow extra cellular deposits under the retinal 
pigment epithelium (RPE), called drusen, and pigmentary abnormalities. It is a 
progressive disorder, ultimately leading to either dry (geographic atrophic) or wet 
(neovascular) late AMD, end stages of AMD that usually are associated with severe 
visual acuity loss. The dry variant of late AMD is characterized by gradual degen-
eration over the years of the RPE, leading to a loss of photoreceptors.2 Wet AMD 
is characterized by leakage from or growth of abnormal blood vessels under the 
retina leading to RPE detachment or subretinal hemorrhage, resulting in fibrovas-
cular disciform scarring. AMD is the leading cause of irreversible blindness in the 
Western world,3-5 and its prevalence is estimated to double by 2020.6 Loss of central 
visual function results in the inability to perform daily activities such as, reading, 
identifying faces, fine detailed working or driving. The etiology of AMD is still not 
clear. Research points to AMD as a complex disorder in which genetic and environ-
mental factors interact. 
Of the few available treatments, laser photocoagulation, photodynamic therapy 
or intraocular injection of vascular endothelial growth factor (VEGF) inhibitors can 
delay the progression of beginning wet AMD in a limited number of patients. An 
increased expression of VEGF was demonstrated in the RPE and choroid of postmor-
tem eyes with early AMD.7 Recently, VEGF inhibitors, such as pegaptanib sodium 
(Macugen), ranibizumab (Lucentis), and bevacizumab (Avastin) became available 
for wet AMD. VEGF inhibitors can prevent the development of sub retinal neovas-
cular membranes, and decrease the permeability of their blood vessels.8 This could 
delay vision loss, and even improve the visual function of patients with beginning 
wet AMD. 
VEGF (also referred to as VEGF-A) is an endothelial cell-specific mitogen, that 
induces normal and abnormal angiogenesis, and is a potent mediator of vascular 
permeability.9 The VEGF gene is located on chromosome 6p21.3 and the coding 
region spans approximately 14 kb.10, 11 Alternative exon splicing produces several 
VEGF isoforms, named according to the number of amino acids, VEGF121 , VEGF145, 
VEGF165 (the most common isoform), VEGF183, VEGF189, and VEGF206. 
12 The VEGF121, 
VEGF183, and VEGF189 isoforms are expressed in various tissues, while VEGF165 is the 
most abundantly expressed isoform. In contrast, VEGF145 and VEGF206 are less abun-
dant.13 The different isoforms have varying degrees of angiogenic properties; it has 
been suggested that either VEGF121 or VEGF165 has the strongest angiogenic proper-
ties.13 Pegaptanib sodium inhibits only the VEGF165 isoform, while ranibizumab and 
bevacizumab should inhibit all VEGF isoforms.14 Several different single nucleotide 
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polymorphisms (SNPs) have been described in the VEGF gene, including three rela-
tively common SNPs that may influence VEGF expression. The C-2578A (rs699947) 
and G-1154A (rs1570360) SNPs are located in the promoter region and the G-634C 
(rs2010963) SNP is located in the 5’ untranslated region of the gene. These SNPs in 
the VEGF gene are associated with VEGF production,15-17 and with several different 
diseases, such as diabetic retinopathy,15 atherosclerosis,18 chronic heart failure,19 
ankylosing spondylitis,20 Alzheimer’s disease,21 and cancer.22-24 
VEGF plays a central role in the regulation of angiogenesis. Therefore, we hypoth-
esized that individual functional VEGF SNPs and haplotypes would be associated 
with early and especially wet late AMD.
methods
Population
The Rotterdam Study is an ongoing prospective, population-based cohort study 
investigating the incidence and determinants of chronic disabling diseases in the 
elderly. All inhabitants aged 55 years or older living in a suburb of Rotterdam, the 
Netherlands were invited.25 Of the 10,275 eligible individuals, 7983 (78%) participat-
ed. The ophthalmologic part of the study started after screening of the participants 
had begun, leading to 6780 (also 78% response) ophthalmic participants. The tenets 
of the Declaration of Helsinki were followed and the appropriate medical ethics 
committees approved of the study. All participants signed an informed consent and 
gave permission to retrieve information from medical records. Baseline examina-
tions, including a home interview and physical examinations at the research center, 
took place from 1990 till 1993 and were followed by three examinations from 1993 
to 1994 (response rate 88%), from 1997 to 1999 (response rate 80%) and from 2000 
till the end of 2004 (response rate 74%). 
AMD definition
For the diagnosis of AMD, 35° color pictures were taken of the macular area of 
each eye (Topcon TRV-50VT fundus camera, Topcon Corporation, Tokyo, Japan) 
after dilatation of the pupils with tropicamide 0.5% and phenylephrine 5%. These 
transparencies, and, in the last follow-up, digitized images, were graded with 12.5x 
magnification according to the International Classification and Grading System 26 
by the same two trained professionals grading AMD from baseline on, who were 
masked for all other determinants.27, 28 In this system, all AMD fundus signs within a 
standard circle (diameter 6 mm) around the fovea are recorded. We only changed 
the terminology from early and late ARM in early and late AMD and categorized the 
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range of AMD fundus signs into five mutually exclusive stages 0 to 4 that had an 
increasing risk of late AMD.28
No AMD was defined as stage 0, no signs of AMD at all or only hard drusen (< 63 μm), 
and stage 1 as soft distinct drusen (≥ 63 μm), or pigmentary abnormalities. Because 
for our analyses we wanted to have a clear separation between participants with 
no AMD and the numerous participants with only one or two soft distinct drusen 
classified as stage 1, we considered stage 1 as no AMD in the present analyses. We 
included as early AMD stage 2, soft indistinct drusen (≥ 125 μm) or reticular drusen 
only or soft distinct drusen (≥ 63 μm) with pigmentary abnormalities, and stage 3, 
soft indistinct drusen (≥ 125 μm) or reticular drusen with pigmentary abnormalities. 
Stage 4 was similar to late AMD and was subdivided in dry (geographic atrophy) and 
wet (neovascular) AMD.28 A person was classified according to the highest stage of 
AMD in either eye and in case of both dry and wet AMD in either eye as wet AMD. 
Early incident AMD (iAMD) was defined as no AMD at baseline and early AMD in 
at least one eye at follow-up. Late iAMD was classified as either no or early AMD 
at baseline and presence of late AMD in either eye at follow-up. Lesions that were 
considered to be the result of other disease, such as diabetic retinopathy, chorioreti-
nitis, high myopia, trauma, angioid streaks, or photocoagulation for reasons other 
than wet AMD, were excluded from AMD classification.
Genotyping
All participants were genotyped for the C-2578A, G-1154A, and G-634C SNPs of the 
VEGF gene. These polymorphisms have been described at http://www.ncbi.nlm.nih.
gov/SNP under the identification numbers rs699947 (C-2578A), rs1570360 (G-1154A), 
and rs2010963 (G-634C). Genotyping was performed, regardless of disease status, 
on baseline blood samples that were acquired by venapuncture and stored at –80°C. 
DNA was isolated according to standard procedures. Genotypes were determined 
in 2-ng genomic DNA using Taqman allelic discrimination assays. Primer and probe 
sequences were optimized using the SNP assay-by-design service of Applied Biosys-
tems. For details see http://store.appliedbiosystems.com. Reactions were performed 
on the Taqman Prism 7900HT 384 wells format. We also determined haplotypes, to 
enhance genetic resolution. Haplotype alleles present in the population were inferred 
by means of the haplo.em function of the program Haplo.Stats (http://cran.r-project.
org/src/contrib/Descriptions/haplo.stats.html), which computes maximum likelihood 
estimates of haplotype probabilities.29, 30 Haplotypes were considered rare when their 
frequency was 1% or less. This resulted in four common haplotypes that describe 
> 99% of our population. Haplotype alleles were coded as haplotype numbers 1 
through 4 in order of decreasing frequency in the population: coding from C-2578A, 
G-1154A, and G-634C, haplotype 1 = C-G-C, 2 = A-A-G, 3 = A-G-G and 4 = C-G-G.
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Assessment of confounders
Information on all potential confounders was collected at baseline. During a home 
interview, trained research assistants asked participants for their smoking habits. 
Smoking was categorized as current, past or never smoker. Systolic and diastolic blood 
pressures were measured twice at the right brachial artery in a sitting position with a 
random zero sphygmomanometer. The average of these two measurements was used 
to determine blood pressure levels. Body mass index (BMI) was calculated as weight 
in kilograms divided by height in meters squared (kg/m2). Non-fasting blood samples 
were obtained from all participants. Serum total cholesterol and high-density lipopro-
tein (HDL) levels were measured by an automated enzymatic procedure. Genotypes of 
the complement factor H (CFH Y402H) SNP (1277 T/C, rs1061170), were determined in 
2-ng genomic DNA extracted according to standard procedures from leukocytes with 
the Taqman allelic discrimination assay (Applied Biosystems, Foster City, California).
Population for analysis
At baseline, gradable fundus transparencies were available on 6418 participants, of 
whom 476 (7.4%) had early AMD and 106 (1.7%) late AMD. Of the 6312 persons at 
risk for any AMD, 4914 (77.9% of those at risk) participated in at least one follow-up 
examination. Persons did not participate in follow-up examinations due to refusal, 
death or loss to follow-up. Our study population consisted of 4228 (67.0% of those 
at risk) participants from whom blood specimens were available for VEGF genotyp-
ing. Genotype data were missing for persons who at baseline only had an interview 
and did not visit the research center, refused blood sampling, or of whom no blood 
was available due to random logistic reasons.
Data analysis
The observed genotype distributions were compared using Pearson’s chi-square test 
to determine if they were in Hardy Weinberg equilibrium. The Common allele was 
defined as the allele with the highest frequency. Persons homozygous for the com-
mon allele were used as the reference category. Cox proportional hazards regres-
sion analyses were used to investigate possible associations between the individual 
C-2578A, G-1154A, and G-634C SNPs, and iAMD. Follow-up time in years was used 
as the time axis of the model. All analyses were adjusted for age and sex, and were 
performed using SPSS 11.0 (SPSS Inc., Chicago, USA). To test the association of VEGF 
gene haplotypes and iAMD, we used the program Haplo.Stats.29, 30 The probability for 
each haplotype pair in each individual was assigned and next an individual’s pheno-
type was directly modelled as a function of each inferred haplotype pair, weighted 
by their estimated probability, to account for haplotype ambiguity. The haplo.glm 
function of Haplo.Stats was used to investigate these associations by computing 
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odds ratios. The most frequent haplotype in our population served as the reference 
category. All analyses were adjusted for age, sex and follow-up time. Haplo.em and 
haplo.glm were implemented in the Haplo.Stats software using the R language.
results
Table 1 shows the baseline characteristics of the study population on whom geno-
type data of the VEGF C-2578A, G-1154A, and G-634C SNPs were available. After 
table 1: Baseline characteristics of the study population at risk for AMD (n = 4228)
Variable
Age, years 67,0 (7.6)
Sex, female (%) 2456 (58.1)
Smoking status (%)
 Never 1397 (33.3)
 Former 1837 (43.4)
 Current 956 (22.8)
Diabetes Mellitus (%) 354 (8.4)
Body Mass Index, kg/m 2 26.3 (3.6)
Systolic blood pressure, mm Hg 137.6 (21.4)
Diastolic blood pressure, mm Hg 73.8 (11.0)
Total cholesterol, mmol/L 6.7 (1.2)
HDL cholesterol, mmol/L 1.3 (0.4)
Complement Factor H Y402H SNP (%)
 Non-carrier 1781 (42.9)
 Heterozygous 1850 (44.6)
 Homozygous 519 (12.5)
C-2578A SNP (%)
 CC 1068 (25.3)
 CA 2095 (49.6)
 AA 1065 (25.2)
G-1154A SNP (%)
 GG 1911 (45.2)
 GA 1832 (43.3)
 AA 485 (11.5)
G-634C SNP (%)
 GG 1825 (43.2)
 GC 1939 (45.9)
 CC 464 (11.0)
* Means and standard deviations between brackets, unless otherwise indicated
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an average follow-up time of 7.4 (SD 3.9) years, 603 (14.3%) persons had iAMD, 
514 (12.2%) early iAMD, and 89 (2.1%) late iAMD, of whom 35 were dry and 54 wet 
iAMD. All genotype distributions were in Hardy-Weinberg equilibrium. Using the 
HapMap website (htpp://www.hapmap.org), the SNPs were found to lie in one link-
age disequilibrium block. The frequencies of VEGF genotypes were: -2578 CC 25.3%, 
CA 49.6%, AA 25.2%; -1154 GG 45.2%, GA 43.3%, AA 11.5%; and -634 GG 43.2%, 
GC 45.9%, CC 11.0%. Table 2 shows that genotypes were not associated with early 
or late iAMD. Because we particularly expected an association between genotypes 
and wet iAMD, we stratified late iAMD into the dry and wet forms. Genotypes were 
associated with neither (Table 2). Additional adjustment for smoking, systolic and 
diastolic blood pressure, total and HDL cholesterol, body mass index, and the com-
plement factor H Y402H SNP did not essentially change our results (data not shown). 
Haplotype alleles were present in the following frequencies: haplotype 1 (C-G-C) in 
33.8%, haplotype 2 (A-A-G) in 33.0%, haplotype 3 (A-G-G) in 16.9%, haplotype 4 
(C-G-G) in 16.1%, and the remaining haplotypes in less than 0.2%. VEGF haplotypes 
were neither associated with early or late iAMD, dry or wet type (Table 3).
table 2: SNPs in the VEGF gene and the risk of early or late iAMD, stratified by type of late iAMD.
Hazard ratios adjusted for age and sex (95% CI)
Early iAMD Late iAMD Dry iAMD Wet iAMD
VEGF SNP
C-2578A
CC 1.00 1.00 1.00 1.00
CA 0.99 (0.78-1.26) 0.83 (0.47-1.46) 0.86 (0.33-2.22) 0.80 (0.39-1.62)
AA 0.94 (0.77-1.17) 0.82 (0.50-1.35) 1.02 (0.46-2.27) 0.71 (0.38-1.32)
G-1154A
GG 1.00 1.00 1.00 1.00
GA 0.93 (0.78-1.12) 0.78 (0.50-1.22) 1.04 (0.52-2.09) 0.64 (0.36-1.14)
AA 0.81 (0.60-1.09) 0.87 (0.43-1.72) 0.76 (0.22-2.62) 0.91 (0.40-2.09)
G-634C
GG 1.00 1.00 1.00 1.00
GC 0.96 (0.80-1.15) 1.00 (0.64-1.56) 1.17 (0.59-2.32) 0.91 (0.51-1.62)
CC 1.02 (0.77-1.35) 1.00 (0.50-2.00) 0.52 (0.12-2.29) 1.32 (0.59-2.93)
table 3: Haplotypes of the VEGF gene and the risk of early or late iAMD, stratified by type of late iAMD.
Odd ratios adjusted for age, sex, and follow-up time (95% CI)
Early iAMD Late iAMD Dry iAMD Wet iAMD
Haplotype 1 (C-G-C) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Haplotype 2 (A-A-G) 0.93 (0.79-1.10) 0.93 (0.64-1.36) 1.06 (0.59-1.93) 0.87 (0.54-1.40)
Haplotype 3 (A-G-G) 1.10 (0.91-1.34) 0.93 (0.59-1.48) 0.96 (0.46-2.02) 0.92 (0.52-1.64)
Haplotype 4 (C-G-G) 1.00 (0.82-1.22) 1.11 (0.72-1.73) 1.30 (0.66-2.56) 1.02 (0.58-1.79)
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discussion
In our cohort study, we were unable to demonstrate an association between three 
common SNPs in the VEGF gene and iAMD. We also studied haplotypes because 
susceptibility to complex diseases is likely attributable to multiple alleles whose col-
lective effects may be better predicted by determining the full haplotype informa-
tion.31 Also haplotype analyses demonstrated no association. Adjusting for possible 
confounders did not alter these findings. 
Strengths of our study are its population-based design, the large study sample, which 
increases the reliability of our findings, and the standardized way in which fundus 
pictures were graded for diagnosing AMD. In contrast to case-control studies, the 
prospective nature of our study makes our results less prone to survival bias. Limita-
tions are loss to follow-up, due to the fact that older and diseased persons were less 
likely to participate, resulting in a healthier study population. This may lead to an 
underestimation of the strength of the associations. Genetic association studies can 
be influenced by population heterogeneity. In our study, approximately 99% of the 
participants were white and, therefore, represent an ethnically homogeneous and 
representative sample of the population from the Netherlands. 
The SNPs in the VEGF gene studied in our study were selected because they were 
reported to be associated with the production of VEGF.15-17 Several other studies 
investigated whether these SNPs were associated with a variety of diseases in which 
angiogenesis plays an important role. Although these three functional SNPs in the 
VEGF gene were not associated with iAMD, we cannot exclude that other SNPs locat-
ed on the VEGF gene might be so. However, most other SNPs that were reported so 
far in the VEGF gene are nonfunctional. The VEGF gene is quite polymorphic and, 
therefore, when the effect of a single SNP is not large, the effect of several SNPs may 
determine the production of VEGF, and thus its clinical manifestations.20 Although 
our study population is large, we cannot exclude that we missed small effects of 
the VEGF SNPs and haplotypes that we studied, especially in our end stage-specific 
analyses. Replication in other large population-based studies is therefore necessary. 
Another possibility is that the true associations between these SNPs and AMD may 
not be conspicuous because of unknown gene-gene or gene-environment interac-
tions.32 That is why we stratified the individual SNP analyses on smoking and CFH, 
two major risk factors for AMD, but found no associations (data not shown). 
Two more studies recently examined the association between SNPs in the VEGF 
gene and AMD. In a family-based and case-control dataset linkage was found.33 
Their VEGF SNP hCV8311614 is identical to the G-634C (rs2010963) SNP, also known 
as C+405G. They also found a significant association with the G-634C SNP in the 
VEGF gene and wet AMD in the case-control dataset.33 A clinic-based case-control 
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study could not find an association between the individual G-634C SNP and wet 
AMD.34 However, they combined nine SNPs in the promoter and 5’UTR region in 
order to form haplotypes, including the G-634C SNP, and found an association with 
wet AMD (OR = 18.24, 95% CI 2.25-148.25), although with large confidence limits. 
In addition, haplotype analyses of five intronic SNPs demonstrated two haplotypes 
associated with wet AMD and one haplotype associated with the control group. 
In conclusion, we did not find evidence for a role of three functional SNPs (C-2578A, 
G-1154A, and G-634C) or reconstructed haplotypes in the VEGF gene in the devel-
opment of AMD. Analyzing additional SNPs in the VEGF gene deserves further 
attention in other large population-based studies, because interactions between 
different VEGF SNPs or haplotypes resulting in wet AMD cannot be ruled out for the 
moment.
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General Discussion 107
generAl discussion
The main objective of the studies described in this thesis was to identify environ-
mental and genetic factors that are involved in the pathogenesis of AMD. All studies 
were performed within the context of the Rotterdam Study, a large prospective 
population-based cohort study in participants aged 55 years and older. In this final 
chapter, I will discuss some of the methodological issues in clinical and genetic epi-
demiology, summarize the main findings with their clinical relevance and provide 
suggestions for future research topics.
methodologicAl considerAtions
Clinical epidemiology
Using a large prospective population-based cohort has many advantages. Because 
of the prospective design, in which the assessment of the risk factor occurred before 
the onset of the disease, a temporal relationship can be determined. This supports 
causality, given that possible biases are adequately dealt with. Our follow-up dura-
tion was long, and extensive information on several potential confounders was 
available on all participants. 
Precision determines the reproducibility of measurement of the point estimates. 
The large cohort increases the reliability of the associations found, by minimizing 
random error, or increasing precision. After stratification by type of end stage, the 
number of people who developed dry and wet late incident AMD (iAMD) was lim-
ited, therefore precision could be a concern in our end stage-specific analyses. 
The validity of a study can be divided into external, which refers to generalizability, 
and internal, which involves restricting systematic error or bias. External validity can 
only be addressed if internal validity is established. A study is internally valid if it 
represents the truth for the individuals studied, and the results cannot be explained 
by bias or confounding. 
In general, three types of bias can be identified: selection bias, information bias, 
and confounding bias. Selection bias occurs if the relation between exposure and 
disease is different for persons who participate compared to those who are theo-
retically eligible, including non-participants. Of the 10,275 eligible individuals at 
baseline, 7983 (78%) participated. The ophthalmologic part of the study started 
after screening of the participants had begun, leading to 6780 (also 78% response) 
ophthalmic participants. We have a good response rate, thereby limiting the pos-
sibility of selection bias. In cohort studies, loss to follow-up is another important 
source for selection bias. In our study, it is particularly important because our cohort 
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was not continuously monitored and therefore participation at the follow-up visits 
was crucial. Data from medical files from ophthalmologists or general practitioners 
often were not detailed enough to make a diagnosis of AMD according to our cri-
teria. Persons who refused to participate or were lost to follow-up were older and 
less healthy.1 This means that we investigated a relatively healthier cohort, and this 
could cause an underestimation of the associations found. However, we think that 
the direction of the associations we found was not affected by this. 
Another threat to validity is information bias, which results from misclassification of 
disease or determinant. This misclassification can be non-differential or differential. 
Non-differential misclassification, which is random, generally leads to a dilution of 
the effect. We made great effort to avoid this by using from baseline on the same 
two well-trained professionals to grade AMD in a standardized way. Differential mis-
classification is a distortion of findings that results from misclassification of the out-
come that is related to the determinant or vice versa. This could either exaggerate or 
underestimate an effect. Differential misclassification of the determinant is unlikely, 
because in our prospective study the exposure was measured before the onset of 
AMD. This also holds for missing data caused by failure of equipment, absence of 
a research assistant, or refusal of persons to participate in specific examinations. 
These data were collected at baseline, and therefore their absence cannot be associ-
ated with iAMD. Differential misclassification of AMD is also unlikely, because the 
persons who graded AMD were masked for exposure status of the cases. 
Confounding may be considered a confusion of the effect under study with that of 
an extraneous factor. Something can only be a confounder when it is associated with 
both the determinant and the outcome under study. In addition, a confounder may 
not be an intermediate step in the causal pathway between exposure and disease. 
In our studies we dealt with confounding by adjusting for potential confounders. 
Age is probably the most important confounder in studies investigating associa-
tions with AMD. We therefore included age as a potential confounder in all analyses. 
Although it is not likely that sex is associated with AMD, we considered it to be a 
potential confounder by convention. Because smoking and the complement factor 
H Y402H SNP are major risk factors associated with AMD, we also included these 
potential confounders in our analyses. Although we adjusted for several potential 
confounders, the possibility of insufficient measurement of confounders (residual 
confounding) or the presence of unknown confounders should always be consid-
ered in observational studies.
Genetic epidemiology
The basic goal of genetic epidemiology is to understand the role of specific genes 
in the etiology of a certain disease. Traditionally, the family-based study design has 
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been used to investigate genetic components of disease, especially in monogenetic 
diseases. Although a variant in the CFH gene explains a considerable number of 
AMD cases, AMD still is considered to be a complex disease, in which multiple genes 
and environmental factors play a role in the pathogenesis. To study genetic fac-
tors of complex disorders, such as AMD, the most commonly used strategy is the 
genetic association study. In this approach, candidate genes are selected, based 
on their biological plausibility in the pathogenesis of the disease, their location 
or because they were found in previous association studies. After selection of the 
candidate gene, it is tested whether a potentially interesting polymorphism in this 
gene occurs more frequently in cases than in controls. Because in this thesis we 
used this approach in identifying genetic risk factors for AMD, we will only discuss 
methodological considerations of genetic association studies. 
The main advantage of these association studies is the ability to detect the influence 
of genes with moderate to small effects. In addition, unrelated persons are studied 
instead of families, thereby facilitating data collection substantially. On the other 
hand, cohorts for association studies on late-onset diseases are less often available. 
Potential cases may have died or did not yet show the clinical signs of AMD, while 
they might develop the disease in the near future leading to false-negative results.2 
Spurious associations may occur when a variant is in linkage disequilibrium with a 
nearby variant, which is the truly causative disease polymorphism.3 Even in well-
performed studies the question remains whether a polymorphism itself causes the 
disease, or the association can be explained by linkage equilibrium. An important 
problem in genetic association studies is inconsistency in results and absence of 
reproducibility of initial positive findings.4 In general, this can be attributed to lack 
of statistical power, effect modification by other genetic or environmental factors, 
and population stratification. Complex diseases, such as AMD, are believed to result 
from several genes with usually individual small effects interacting with environ-
mental risk factors. Consequently the effect of a genetic polymorphism may be 
small and may not reach significance in a genetic association study.5 Because we 
used data from the Rotterdam Study, a large study population for our analyses, this 
problem may have partly been overcome. However in our end stage-specific analy-
ses the number of cases was small and therefore we could not exclude the possibil-
ity of false-negative findings. Statistical power can also be increased by formation 
of haplotypes, that describe the total common variation of a gene.6 Differences in 
effect size could be attributed to effect modification by other genetic or environ-
mental factors, if these factors differ between study populations.4 Therefore it is 
important to have reliable data on specific environmental risk factors, which may 
interact with genetic factors, when performing a genetic association study. Popula-
tion stratification is an important problem in genetic association studies. When the 
110
Ch
ap
te
r 4
study population consists of a mixture of two or more subpopulations that have 
different allele frequencies and disease risks, associations between genotype and 
outcome could be confounded by population stratification.4 By using restriction or 
matching by demographic background, population stratification can be controlled 
for. In the Rotterdam Study confounding by population stratification is not likely, 
because approximately 99% of the participants were white persons from the Neth-
erlands and therefore represent an ethnically homogeneous and representative 
sample of the Dutch population.
When these issues are addressed, genetic association studies offer a powerful 
approach in identifying genetic risk factors for complex diseases. 
mAin findings And their clinicAl relevAnce
Antioxidants
Oxidative stress, which refers to cellular damage caused by reactive oxygen inter-
mediates, has been implicated in the pathogenesis of many age-related disorders 
such as AMD.7, 8 The retina is especially vulnerable for damage caused by oxidative 
stress because of the high oxygen consumption, the cumulative exposure to light, 
and the high amount of polyunsaturated fatty acids and photosensitizers.9 In the 
multicenter randomized placebo-controlled Age-Related Eye Disease study, sup-
plements containing 5 to 13 times the recommended daily dose of beta carotene, 
vitamins C and E, and zinc significantly reduced the risk of progression to late AMD. 
To further explore this hypothesis, we studied dietary intake of antioxidant micro-
nutrients, including carotenoids, vitamins, and trace elements, in relation to the risk 
of AMD. We found that beta carotene, vitamins C and E, and zinc have a protective 
effect on the development of AMD. We believe that based on our findings and on 
data from the Age-Related Eye Disease study, it is justified to give dietary advice and 
nutritional supplementation if dietary intake is expected to remain insufficient in 
elderly persons with an increased risk of AMD, such as those with early AMD or with 
several sibs with AMD.
CRP
It has been suggested that inflammation plays a role in the etiology of AMD.2, 10-12 CRP 
is a non-specific marker of inflammatory or infectious processes. Two clinic-based 
cross-sectional studies and one similar longitudinal study reported associations 
between CRP levels and AMD.13-15 We attempted to confirm these data in a popula-
tion-based cohort study. We found that persons with a relatively high HsCRP level 
(> 1.73 mg/L) within the normal range, have a significant higher risk of early and late 
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iAMD. Reducing levels of CRP might have a favourable impact on the development 
of AMD. High body mass index as well as smoking increase CRP levels and moderate 
alcohol intake, diets with a low glycemic index, statins and multivitamins reduce 
them.16, 17 By optimizing these lifestyle factors, the risk of AMD should decrease. In 
the future, CRP levels potentially could give clinically relevant predictive informa-
tion, in addition to other known risk, in profiling the risk of AMD in individuals. At 
this moment we believe that further research is warranted and that a possible pre-
dictive role of serum CRP levels should be critically evaluated.
Alcohol consumption
Moderate alcohol consumption may protect against AMD, because of its positive 
effect on cardiovascular disease.18-22 Conversely, alcohol itself may be a source of 
oxidative stress, or may interfere with mechanisms which protect against oxidative 
damage.22 Several studies have investigated associations between alcohol consump-
tion and AMD, with conflicting results.23-31 Because of the importance of identifying 
modifiable risk factors for AMD we also examined this potential association. We 
were unable to find an association between overall or specific alcohol consumption 
and early or late iAMD. After stratification by type of end stage, with higher alcohol 
consumption, point estimates were increasing for dry iAMD and decreasing for wet 
iAMD. However, associations did not reach significance. The lack of consistent find-
ings among studies suggests that it is not likely that alcohol consumption is mark-
edly associated with AMD. Patients should be warned, however, that high alcohol 
consumption is not beneficial for their general health.
Estrogen receptor 1
Diminished exposure to endogenous estrogens, like in early menopause, have 
been associated with an increased risk of AMD and exposure to endogenous or 
postmenopausal exogenous estrogens reduces this risk,32-35 although other studies 
refute this.36, 37 The effect of estrogen is mediated through intracellular estrogen 
receptors. We examined the role of two polymorphisms in the estrogen receptor 1 
(ESR1) gene on the risk of AMD in men and women. Recently ESR1 haplotype 1 
was associated with serum estradiol levels in postmenopausal women,38 We dem-
onstrated an increased risk of late iAMD, and especially wet late iAMD in persons 
carrying ESR1 haplotype 1. After stratification on sex, this association was most pro-
nounced in women. This confirms a possible pathophysiological role for estrogen 
in the development of AMD. The clinical relevance of this finding is less obvious at 
this time.
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Insulin-like growth factor-1
It has been suggested that pro-angiogenic growth factors, such as insulin-like 
growth factor-1 (IGF-1) are involved in the development of wet late AMD.39-41 IGF-I is 
a ubiquitous polypeptide that regulates growth, differentiation and proliferation of 
many types of cells, including human RPE cells. We investigated whether a polymor-
phism in the IGF-1 gene, which is associated with circulating IGF-1 levels,42 is also 
associated with AMD, particularly with wet AMD. This specific polymorphism in the 
IGF-1 gene was not associated with early or late iAMD. After stratification by type of 
end stage we also could not demonstrate an association with dry or wet late iAMD. 
In case the effect of this polymorphism is small, we would not find an association, 
especially in our end stage-specific analyses, because of lack of power. Our study 
suggests that this polymorphism in the IGF-1 gene is no major contributor to the 
genetic susceptibility to AMD.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a glycoprotein and is a growth factor 
specific for endothelial cells.43 It induces normal and abnormal angiogenesis and 
is a potent inducer of vascular permeability.44 Recently, VEGF inhibitors became 
available for the treatment of wet late AMD. We investigated whether three poly-
morphisms in the VEGF gene, associated with VEGF levels,45-47 and several differ-
ent diseases, such as diabetic retinopathy, atherosclerosis, chronic heart failure, 
ankylosing spondylitis, Alzheimer’s disease, and cancer,48-54 are also associated with 
AMD, and especially wet AMD. Neither the individual functional polymorphisms nor 
the constructed haplotypes showed an association with early, late dry, or wet iAMD. 
Our study suggests that these three SNPs are not associated with the pathogenesis 
of AMD.
suggestions for future reseArch
Therapeutical strategies are still limited, although over the last decade we obtained 
more insight in the etiology of AMD. A major challenge in the next years is to further 
unravel the mechanisms responsible for the development of drusen, and dry as well 
as wet AMD. In this way the development of treatments that may slow down, stop, 
or preferably prevent the disease will be stimulated.
Only a few modifiable risk factors for AMD have been identified thus far. Exposure 
to risk factors for AMD might occur early in life and over a long period of time. This 
could explain why associations are not recognised in studies with a short follow-up 
time and of older persons. In order to identify environmental risk factors for AMD 
General Discussion 113
it is important to study large populations with a long-term follow-up. It is often 
difficult to compare studies due to different classifications of exposure and AMD. 
Therefore studies should use standardized definitions of AMD and the exposures 
studied. Even large studies, such as the Rotterdam Study, suffer from the problem of 
relatively small numbers of persons with late AMD. A solution would be collabora-
tion between researchers in order to pool their data. This would improve statistical 
power, and consequently will give more precise point estimates.
Several studies have attempted to identify susceptibility genes for AMD. Until 
recently, there have been relatively few breakthroughs in our understanding of 
the genetics of AMD. In the past year, researchers have identified a major risk 
variant in the complement factor H (CFH) gene,55-58 and recent reports suggest 
that SNPs in the LOC387715, C2/FB and HTRA1 genes are also major risk factors 
for AMD.59-62 Besides CFH, genetic association studies have been mostly inconclu-
sive. Verification of reported associations is therefore an area of interest for the 
future. Both positive, as well as negative studies should be replicated, preferably 
in large population-based cohorts. Most genetic association studies have investi-
gated only one or two gene variants. Future studies should attempt to examine 
as many polymorphisms as possible while adjusting for multiple testing.63 Genetic 
association studies seem to be a useful strategy in identifying genetic risk factors 
for AMD. However, only the genetic variation in a candidate gene is studied, so 
genetic loci associated with AMD which are not in linkage disequilibrium with the 
gene studied, remain undetected. The genome-wide association study, which is 
planned for all Rotterdam Study participants, might be a good approach to cir-
cumvent this disadvantage of genetic association studies. An important question 
is how much is already explained by known genes and how to find new genes. 
It remains unclear whether we have to search for common variants with small 
effects, or rare ones with large effects.
The finding that late AMD is more prevalent in whites than blacks combined with the 
fact that genotype frequencies of CFH are similar in whites and blacks, suggests that 
this gene alone cannot explain the pathogenesis of AMD. Previously, most studies 
have investigated the effect of only genetic or environmental factors. Because AMD 
is most likely to be a complex disease, epidemiological studies should focus their 
attention on gene-environmental interactions. Because of differences in genotype 
distributions and environmental factors across populations, studies investigating 
these interactions should be performed in different ethnic groups.
At this moment, there are no animal models that faithfully imitate all phases of 
AMD. The development of advanced animal models that capture the complex inter-
actions between genes and environment would help to elucidate its pathogenesis 
and the development of therapeutic strategies. Until such complex animal models 
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are developed, simple animal models and in vitro models of specific characteristics 
of AMD are still necessary.
In conclusion, if and when the complex pathogenesis of AMD will be elucidated 
remains unanswered. However, considerable progress has been made over the last 
25 years and promising results are emerging continuously. Better understanding 
of the genetics of AMD, longer follow-up from large population-based studies, and 
if possible clinical trails should ultimately lead to the development of therapeutic 
strategies which can prevent or treat AMD.
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Aging macula disorder (AMD) is the leading cause of irreversible blindness among 
persons above age 65 years in the Western world. Due to the growing elderly pop-
ulation it is becoming an important issue in health care. AMD affects the central 
part of the retina, known as the macula lutea, ultimately leading to loss of visual 
function. Despite intensive research in the last decades, only in a minority of the 
cases treatment strategies are available that can partially restore visual function. 
Currently, AMD is considered to be a multifactorial disease, in which environmental 
and genetic risk factors interact. The main objective of the research in this thesis was 
to identify new risk factors for this blinding disease. The studies mentioned were all 
embedded in the Rotterdam Study. This is a large prospective population-based 
cohort study among 7983 persons aged 55 years and older living in a suburb of 
Rotterdam, in which most potential risk factors were assessed at baseline between 
1990 and 1993. At the research centre fundus photographs were made, which were 
graded according to an International Classification and Grading System for AMD 
by two trained professionals in order to identify participants with no, early or late 
AMD. 
chapter 1 is a brief introduction to the work presented in this thesis.
chapter 2 deals with the relation between environmental factors and risk of AMD. In 
chapter 2.1 the relationship between diet and AMD is presented. At baseline, par-
ticipants were asked about their dietary habits, and subsequently these data were 
converted to specific nutrient intake per day. High dietary intake of beta carotene, 
vitamins C and E, and zinc was associated with a reduced risk of AMD. In chapter 
2.2 the influence of a serum marker of inflammation on the risk of AMD was inves-
tigated. Higher serum C-reactive protein levels were associated with an increased 
risk of AMD. This finding confirms earlier observational clinic-based studies that 
inflammation is involved in the pathogenesis of AMD in the general population. 
chapter 2.3 describes the relation between alcohol consumption and AMD. Mod-
erate alcohol consumption is associated with a decreased risk of cardiovascular 
disease. Because vascular disease has been associated with AMD, moderate alcohol 
consumption could also protect against the development of AMD. On the other 
hand, alcohol can cause oxidative damage. Alcohol consumption seemed not to be 
a modifiable risk factor for AMD. 
Studies between genetic polymorphisms, or common DNA sequence variations, 
and AMD are presented in chapter 3. In the past we found in the Rotterdam Study 
that estrogen might be involved in the pathogenesis of AMD. Therefore in chapter 
3.1 the association between polymorphisms in the estrogen receptor 1 (ESR1) gene, 
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related to serum estradiol levels in postmenopausal women, and AMD was investi-
gated. Certain polymorphisms in the ESR1 gene were associated with an increased 
risk of AMD, and this was most pronounced in postmenopausal women. In chapter 
3.2 the role of a cytosine-adenosine (CA) repeat polymorphism in the promoter 
region of the insulin-like growth factor 1 (IGF-1) gene, related to serum IGF-1 levels, 
and AMD is examined. Pro-angiogenic factors, such as IGF-1, are believed to play a 
role in the pathogenesis of AMD. No association was found between this polymor-
phism and AMD. Vascular endothelial growth factor (VEGF) induces angiogenesis, 
and is a target for therapeutic inhibition of wet AMD. In chapter 3.3 the role of 
three polymorphisms in the VEGF gene, associated with several different diseases 
and VEGF production, on the development of AMD was investigated. No association 
was found between these three polymorphisms in the VEGF gene and AMD.
In the general discussion in chapter 4, several methodological issues in clinical and 
genetic epidemiology are commented on in order to facilitate a proper interpreta-
tion of the study results that are described in this thesis. Furthermore, I discussed 
the main findings and their clinical relevance and finally provided suggestions for 
future research on AMD.
Samenvatting

Samenvatting 127
Ouderdoms macula aandoening (OMA) is de belangrijkste oorzaak van irreversibele 
blindheid bij mensen boven de 65 jaar in de Westerse wereld. Door de toenemende 
vergrijzing zal het een belangrijke kwestie in de gezondheidszorg worden. OMA 
tast het centrale deel van het netvlies, de macula lutea, aan en veroorzaakt in het 
eind stadium van OMA ernstig verlies van zicht. Ondanks recente wetenschappelijke 
doorbraken, zijn er maar voor een kleine groep patiënten behandelingen beschik-
baar die het verlies van zicht gedeeltelijk kunnen herstellen. Volgens de huidige 
inzichten wordt OMA beschouwd als een multifactoriële aandoening die het gevolg 
is van wisselwerking tussen erfelijke aanleg en omgevingsfactoren. De doelstelling 
van het onderzoek beschreven in dit proefschrift, was het identificeren van nieuwe 
risicofactoren voor deze blindmakende ziekte. Alle studies beschreven in dit proef-
schrift zijn gebaseerd op data afkomstig uit het Erasmus Rotterdam Gezondheid en 
Ouderen (ERGO) onderzoek, internationaal bekend als “the Rotterdam Study”. Dit is 
een groot prospectief bevolkingsonderzoek, waaraan 7.983 mannen en vrouwen 
van 55 jaar en ouder, wonend in de Rotterdamse wijk Ommoord, deelnemen. Bij 
aanvang van de studie tussen 1990 en 1993 zijn de deelnemers uitgebreid onder-
zocht en geïnterviewd en zijn er gegevens verzameld over verschillende potentiële 
risicofactoren. Op het onderzoekscentrum zijn foto’s gemaakt van het netvlies, die 
later beoordeeld zijn door twee vakkundige medewerksters, volgens een internati-
onaal classificatie en graderingsysteem speciaal ontwikkeld voor OMA. 
hoofdstuk 1 is een korte inleiding op het werk gepresenteerd in dit proefschrift.
hoofdstuk 2 behandelt de relatie tussen externe factoren en het risico op OMA. 
In hoofdstuk 2.1 wordt de invloed van voeding op het risico op OMA onderzocht. 
Bij aanvang van de studie werd deelnemers gevraagd naar hun voedingsgewoon-
ten, waarna uit deze data de gemiddelde consumptie van specifieke bestandde-
len is berekend. Een relatief grote consumptie van bèta-caroteen, vitamine C en 
E en zink verlaagd het risico op OMA. In hoofdstuk 2.2 is de invloed van een 
ontstekingsmarker in het bloed onderzocht. Hogere concentraties C-reactief pro-
teïne (CRP) waren geassocieerd met een hoger risico op OMA. Dit bevestigt de 
eerder in een klinisch onderzoek aangetoonde rol van ontsteking bij het ontstaan 
van OMA, ook in de algemene bevolking. hoofdstuk 2.3 beschrijft de relatie tus-
sen alcohol inname en OMA. Matige alcohol consumptie was geassocieerd met 
een licht verlaagd risico op hart- en vaatziekten. Omdat OMA geassocieerd is met 
vaatziekten, zou matige alcohol consumptie mogelijk ook een beschermende 
werking kunnen hebben op de ontwikkeling van OMA. Aan de andere kant kan 
alcohol oxidatieve schade veroorzaken. Alcohol consumptie leek geen noemens-
waardige risicofactor voor OMA.
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hoofdstuk 3 bevat enkele studies waarin associaties worden bestudeerd tus-
sen genetische polymorfismen, of veelvoorkomende variaties in DNA volgorde, 
en OMA. Wij vonden in het verleden in het ERGO onderzoek dat een gebrek aan 
vrouwelijke geslachtshormonen, oestrogenen, een rol speelt in het ontstaan van 
OMA. Polymorfismen in het oestrogeen receptor 1 (ESR1) gen zijn gerelateerd aan 
lagere oestradiol spiegels in het bloed van vrouwen na de overgang. In hoofdstuk 
3.1 is daarom de associatie tussen deze ESR1 polymorfismen en OMA onderzocht. 
Bepaalde genetische variaties in het ESR1 gen leidden tot een verhoogd risico op 
OMA, en in het bijzonder bij postmenopauzale vrouwen. In hoofdstuk 3.2 wordt de 
rol van een cytosine-adenosine (CA) repeat polymorfisme in het promoter gebied 
van het insuline-achtige groeifactor 1 (IGF-1) gen, wat gerelateerd is aan circule-
rende IGF-1 spiegels, en OMA onderzocht. Er wordt gedacht dat pro-angiogene 
factoren, zoals IGF-1, een rol spelen in de pathogenese van OMA. Dit polymorfisme 
was niet geassocieerd met de kans op OMA. Vasculaire endotheliale groeifactor 
(VEGF) induceert angiogenese en VEGF-remmers worden gebruikt in de behande-
ling van natte OMA. In hoofdstuk 3.3 is de rol van drie polymorfismen in het VEGF 
gen, die geassocieerd zijn met verschillende aandoeningen en de productie van 
VEGF, op de ontwikkeling van OMA onderzocht. Tussen deze drie polymorfismen 
in het VEGF gen en OMA is geen associatie gevonden.
In de algemene discussie in hoofdstuk 4 worden enkele methodologische pro-
blemen van de klinische en genetische epidemiologie besproken, om een juiste 
interpretatie van de onderzoeken in dit proefschrift te vergemakkelijken. Daarnaast 
bespreek ik de belangrijkste bevindingen en hun klinische relevantie en geef ik sug-
gesties gegeven voor toekomstig onderzoek naar OMA.
D a n k w o o r d
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boekje er nooit zijn gekomen. In de eerste plaats wil ik de duizenden deelnemers 
aan het ERGO onderzoek bedanken die jaar na jaar trouw bleven komen om zich 
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geen favoriet onderdeel is. Zonder deze bereidheid om prikkende oogdruppels te 
ondergaan, zou er geen data zijn en dus geen boekje.
Een aantal mensen wil ik hier in het bijzonder noemen vanwege hun belangrijke 
bijdrage.
Mijn beide promotoren: prof.dr. P.T.V.M. de Jong en prof.dr. A. Hofman.
Beste Paulus, ik heb veel respect gekregen voor je directe en eerlijke aanpak, jouw 
altijd aanwezige klinische blik en de legendarische snelheid waarmee je artikelen 
van commentaar voorziet. Bedankt voor alles wat ik van je geleerd heb. Bert, jouw 
aanstekelijke enthousiasme voor de epidemiologie en het wetenschappelijk onder-
zoek zijn inspirerend. Als enige van mijn promotoren met een kamer op de afde-
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bedanken voor hun bereidheid om zitting te nemen in de kleine commissie en voor 
de inhoudelijke beoordeling van dit proefschrift. Professor van Meurs wil ik tevens 
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ding. Ik verheug me erop om opgeleid te worden onder uw supervisie. 
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nemen aan de grote commissie.
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